WO2023020566A1 - 一种苯并氮杂芳环衍生物及其在医药上的应用 - Google Patents
一种苯并氮杂芳环衍生物及其在医药上的应用 Download PDFInfo
- Publication number
- WO2023020566A1 WO2023020566A1 PCT/CN2022/113216 CN2022113216W WO2023020566A1 WO 2023020566 A1 WO2023020566 A1 WO 2023020566A1 CN 2022113216 W CN2022113216 W CN 2022113216W WO 2023020566 A1 WO2023020566 A1 WO 2023020566A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- substituted
- cyano
- halogen
- alkoxy
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 80
- 239000002207 metabolite Substances 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000012453 solvate Substances 0.000 claims abstract description 39
- 239000000651 prodrug Substances 0.000 claims abstract description 38
- 229940002612 prodrug Drugs 0.000 claims abstract description 38
- 239000013078 crystal Substances 0.000 claims abstract description 36
- 102000003712 Complement factor B Human genes 0.000 claims abstract description 11
- 108090000056 Complement factor B Proteins 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 1010
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 458
- -1 -OCH 2 C(=O)R 1c Chemical group 0.000 claims description 428
- 150000002367 halogens Chemical class 0.000 claims description 414
- 229910052736 halogen Inorganic materials 0.000 claims description 413
- 125000003545 alkoxy group Chemical group 0.000 claims description 392
- 125000000623 heterocyclic group Chemical group 0.000 claims description 344
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 239
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 226
- 229910052739 hydrogen Inorganic materials 0.000 claims description 203
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 175
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 175
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 171
- 125000000304 alkynyl group Chemical group 0.000 claims description 169
- 229910052760 oxygen Inorganic materials 0.000 claims description 165
- 229910052731 fluorine Inorganic materials 0.000 claims description 161
- 229910052794 bromium Inorganic materials 0.000 claims description 154
- 229910052801 chlorine Inorganic materials 0.000 claims description 154
- 229910052757 nitrogen Inorganic materials 0.000 claims description 154
- 229910052717 sulfur Inorganic materials 0.000 claims description 154
- 125000005842 heteroatom Chemical group 0.000 claims description 148
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 132
- 229910052740 iodine Inorganic materials 0.000 claims description 131
- 125000001424 substituent group Chemical group 0.000 claims description 124
- 125000003342 alkenyl group Chemical group 0.000 claims description 122
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 116
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 106
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 106
- 229910052805 deuterium Inorganic materials 0.000 claims description 105
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 98
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 98
- 125000002393 azetidinyl group Chemical group 0.000 claims description 88
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 87
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 87
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 83
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 80
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 79
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 77
- 125000003566 oxetanyl group Chemical group 0.000 claims description 68
- 125000001072 heteroaryl group Chemical group 0.000 claims description 67
- 125000003386 piperidinyl group Chemical group 0.000 claims description 57
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 57
- 125000004193 piperazinyl group Chemical group 0.000 claims description 55
- 125000002757 morpholinyl group Chemical group 0.000 claims description 52
- 125000004076 pyridyl group Chemical group 0.000 claims description 51
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 49
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 47
- 125000002883 imidazolyl group Chemical group 0.000 claims description 46
- 125000002541 furyl group Chemical group 0.000 claims description 43
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 43
- 125000000335 thiazolyl group Chemical group 0.000 claims description 43
- 125000001425 triazolyl group Chemical group 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 42
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 41
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000002971 oxazolyl group Chemical group 0.000 claims description 39
- 125000001544 thienyl group Chemical group 0.000 claims description 39
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 37
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 33
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 30
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 29
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 28
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 25
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 15
- 125000004414 alkyl thio group Chemical group 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 150000001721 carbon Chemical group 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
- 229920002554 vinyl polymer Polymers 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000002053 thietanyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 description 117
- 239000002585 base Substances 0.000 description 23
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 5
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 4
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003943 azolyl group Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 description 1
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Definitions
- the present invention relates to a compound described in general formula (I) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, and its intermediate and preparation method , and its application in the preparation of medicines for treating diseases related to the activity or expression of complement factor B.
- Complement factor B is a component of the alternative pathway of complement, involved in the body's specific and non-specific immune mechanisms, it contains a serine protease (Serine Protease, SP) domain, when activated, it will provide the alternative pathway Catalytic activity of C3 and C5 convertases.
- Complement factor B circulates as an inactive proenzyme (i.e., a zymogen) that is activated only after cleavage by the protein factor D.
- protein factor D can only cleave complement factor B when bound to C3:C3( H2O ) and C3b in the activated form.
- Complement factor B is produced as a single chain protein and is cleaved by factor D to yield two peptide fragments (Ba and Bb).
- the Bb region (containing the SP domain) still binds to C3(H 2 O) and C3b, forming the alternative pathway convertase [C3(H 2 O)Bb and C3bBb].
- the SP domain of Bb has special catalytic activity for the cleavage of C3 molecules.
- Addition of another C3b molecule to the alternative pathway C3 convertase produces a C5 convertase (C3bBbC3b).
- complement factor B is a key enzyme in the activation of the complement alternative pathway and may serve as a suitable target for inhibiting the complement activation pathway.
- the object of the present invention is to provide a compound capable of inhibiting complement factor B or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, and its intermediate and preparation
- the compound of the present invention has good complement factor B inhibitory activity, good inhibition rate of C3a level in vivo, bioavailability and safety.
- the present invention provides a compound described in general formula (I) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, wherein
- the compound of general formula (I) is selected from compounds represented by general formula (Ia), (Ib), (Ic), (Id), (Ie) or (If),
- the compound of general formula (I) is selected from compounds represented by general formula (Id-1) or general formula (Id-2)
- the compound of general formula (I) is selected from compounds represented by general formula (Id-3), general formula (Id-4),
- the compound of general formula (I) is selected from compounds represented by general formula (Id-5), general formula (Id-6), general formula (Id-7), general formula (Id-8),
- R 1 is selected from H, halogen, OH, cyano, NH 2 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy , C 1-4 alkylthio, -WR 1d , C 3-6 carbocyclyl or 4 to 8 membered heterocyclyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbon
- R 1 is selected from R 1A ;
- each R is independently selected from H, F, Cl, Br, I, OH, cyano, NH2 , methyl, ethyl, propyl, isopropyl, t-butyl, methoxy , ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, ethylthio, cyclopropyl, cyclobutyl, -O-cyclopropyl, -O- Cyclobutyl, -O-cyclopentyl, wherein the methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, Proynyl, propargyl, methylthio, ethylthio, cyclopropyl, cyclobutyl, -O-cyclopropyl, methyl, e
- each R1 is independently selected from H, F, Cl, Br, I, OH, cyano, NH2 , -OCD3 , CD3 , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, ethynyl, -CH 2 -cyclopropyl or -O-cyclopropyl;
- each R 1 is independently selected from -OCH 2 F, -OCHF 2 , -OCF 3 ,
- R 1 is selected from H, F, Cl, Br, I, -OCD 3 , CD 3 , methyl, ethyl, propyl, methoxy, ethoxy, isopropoxy, cyclo Propyl, -CH 2 -cyclopropyl or -O-cyclopropyl;
- R 1 is selected from -OCH 3 or -OCD 3 ;
- W is selected from O or S;
- n is selected from 0, 1 or 2;
- p is selected from 0, 1 or 2;
- X1 and X2 are each independently selected from N or CR3 ;
- X 1 is selected from CR 3 and X 2 is selected from CR 3 ;
- X1 is selected from N and X2 is selected from CR3 ;
- X 1 is selected from CR 3 and X 2 is selected from N;
- X is selected from N or CH, and X is selected from N or CH, wherein the CH is optionally substituted with 1 methyl or ethyl;
- X and X are each independently selected from N;
- Y is selected from NR 7 or C(R 7 ) 2 ;
- Y is selected from CR 7 R 7' ;
- Y is selected from NR 7A ;
- Y is selected from C(R 7a ) 2 ;
- Y is selected from C(R 7B ) 2 ;
- Y is selected from n is selected from 1, 2 or 3;
- each R3 is independently selected from H, methyl, or ethyl
- R 2 is selected from halogen, C 1-6 alkyl or C 1-6 alkoxy, wherein the alkyl, alkoxy are optionally further replaced by 0 to 4 selected from H, D, Substituents of halogen, OH, cyano or NH 2 ;
- R 2 is selected from halogen, C 1-4 alkyl or C 1-4 alkoxy, wherein the alkyl, alkoxy are optionally further selected from 0 to 4 selected from H, D, Substituents of halogen, OH, cyano or NH 2 ;
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, t-butyl, methoxy, ethoxy, or isopropoxy, wherein The methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy or isopropoxy groups are optionally further replaced by 0 to 4 selected from H, D, F, Cl, Br, Substituents of I, OH, cyano or NH 2 ;
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, t-butyl, methoxy, ethoxy, or isopropoxy;
- each R is independently selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl;
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl;
- each R2 is independently selected from CD3 , CHD2 , CH2D ;
- each R 2 is independently selected from -CH 3 , -CD 3 ;
- each R6 is independently selected from H, F, Cl, Br, I, OH, NH2 , methyl, ethyl, propyl, isopropyl, t-butyl, methoxy, ethoxy base or isopropoxy;
- each R6 is independently selected from H, F, Cl, Br, I, OH, NH2 , methyl, ethyl, propyl, isopropyl;
- R is selected from H
- 2 R 7B together form the following ring with the carbon to which they are attached:
- R 7' is selected from R 7 ;
- R 7 ' is selected from H, F, OH, NH 2 , methyl, ethyl, methoxy, ethoxy, wherein said methyl, ethyl, methoxy, ethoxy Optionally further substituted by 0 to 4 substituents selected from H, D, F, Cl, Br, CF 3 , OH, methyl, ethyl, methoxy or ethoxy;
- selected from is selected from a single bond or a double bond, when selected from a double bond, R 7' is absent, and middle At most 1 selected from double bonds;
- Ring B is selected from the group consisting of oxetanyl, oxolyl, oxanyl, thietanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, wherein the oxetanyl, oxolyl, oxanyl, thiolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or pipe
- Ring B is selected from the group consisting of oxetanyl, oxolyl, oxanyl, thietanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, wherein the oxetanyl, oxolyl, oxanyl, thiolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or pipe
- R 6 in each independently selected from H, F, Cl, Br, CF 3 , methyl or ethyl;
- R 7 is selected from C 2-4 alkynyl, phenyl, C 3-6 cycloalkyl, 3 to 8 membered heterocycloalkyl or 5-6 membered heteroaryl
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, pyrrolidinyl, piperidinyl , morpholinyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, oxazolyl, iso Oxazolyl, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 'is selected from H, F, OH, NH 2 , or substituted or unsubstituted one of the following groups: methyl, ethyl, propynyl,
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, pyrrolidinyl, piperidinyl , morpholinyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, oxazolyl, iso Oxazolyl, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 'is selected from H, F, OH, NH 2 , or substituted or unsubstituted one of the following groups: methyl, ethyl, propynyl,
- R in is selected from ethynyl, propargyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, wherein said propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl
- the group is optionally further substituted by 0 to 4 substituents selected from H, D, F, Cl, Br, CF 3 , OH, methyl, ethyl, methoxy, ethoxy, cyclopropyl
- R 7 ' is selected from H, F, OH, NH 2 , methyl, ethyl, methoxy, and ethoxy, wherein the methyl, ethyl, methoxy, and ethoxy are optionally further replaced by 0 to 4
- R 7 is selected from R 7B , and two R 7B together form the following ring with the carbon to which they are attached:
- R 7 is selected from R 7A or R 7a ;
- R 7a is selected from F, Cl, Br, I, CF 3 , -CH 2 F, vinyl, ethynyl, propynyl, propargyl, -CH 2 -propynyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -azetidinyl, -CH 2 OCH 3 , -OCH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CF 3.
- each R is independently selected from methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, said methyl, ethyl, Propyl, isopropyl, tert-butyl, methoxy, ethoxy, and isopropoxy are further replaced by 1 to 3 selected from halogen, ethynyl, C 2-4 alkynyl, C 1-4 alkoxy , C 1-4 alkyl substituted C 2-4 alkenyl, C 1-4 alkyl substituted C 2-4 alkynyl, C 1-4 alkyloxy substituted C 1-4 alkoxy, halogen substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, cyano substituted C 1-4 alkyl, C 3-6 cycloalkyl or 3 to 8 membered heterocyclic substituents;
- each R is independently selected from methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, said methyl, ethyl, Propyl, isopropyl, tert-butyl, methoxy, ethoxy, and isopropoxy are further selected from 1 to 3 of F, Cl, Br, I, ethynyl, methoxy, ethoxy, Substituents of CF 3 , -CH 2 F, cyclopropyl, cyclobutyl, azetidinyl or pyrrolidinyl;
- R 6 and R 7 at adjacent positions may form a double bond
- two R 6 and the atoms to which they are attached together form a C 3-6 cycloalkyl or 3-6 membered heterocyclyl, wherein the cycloalkyl or heterocyclyl is optionally further replaced by 0 to 4 selected from H, halogen, OH, O, cyano, NH 2 , C 1-6 alkyl, C 1-6 alkoxy, halogen substituted C 1-6 alkyl, hydroxy substituted C 1-6 alkane substituted by a C 1-6 alkyl substituent substituted by a cyano group or a cyano group, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N;
- two R 6 and the atoms to which they are attached together form cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxolyl, oxanyl, thiolanyl , azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl;
- selected from Indicates a single bond or a double bond, and contains only one double bond
- selected from Its top is connected with R4 ;
- R is selected from C 5-12 carbocyclyl, 5-12 membered heterocyclyl, C 6-12 aryl or 5-12 membered heteroaryl, wherein the carbocyclyl, heterocyclic
- the base, aryl or heteroaryl is optionally further substituted by 0 to 4 R, wherein the heterocyclyl or heteroaryl contains 1 to 4 heteroatoms selected from O, S or N;
- R 4 is selected from C 5-7 monocyclic carbocyclyl, C 5-12 acyclic carbocyclyl, C 5-12 spirocyclic carbocyclyl, C 5-12 bridged ring carbocyclyl , 5 to 7 membered monocyclic heterocyclic group, 5 to 12 membered ring heterocyclic group, 5 to 12 membered spirocyclic heterocyclic group or 5 to 12 membered bridged ring heterocyclic group, C 6-10 aryl or 5 to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or heteroaryl contains 1 to 4 heteroatoms selected from O, S or N;
- R 4 is selected from C 5-6 monocyclic carbocyclyl, C 5-10 acyclic carbocyclyl, C 5-11 spirocyclic carbocyclyl, C 5-12 bridged ring carbocyclyl , 5 to 6 membered monocyclic heterocyclic group, 5 to 10 membered ring heterocyclic group, 5 to 11 membered spirocyclic heterocyclic group, 5 to 12 membered bridged ring heterocyclic group, C 6-10 aryl or 5 to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or heteroaryl contains 1 to 4 heteroatoms selected from O, S or N;
- each R is independently selected from cyclopentyl, cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidinyl, or naphthyl,
- the cyclopentyl, cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidyl or naphthyl are optionally further substituted by 0 to 4 R ;
- each R4 is independently selected from
- R is selected from
- R is selected from Wherein said R is optionally substituted by 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, methyl, ethyl, methoxy or ethoxy;
- R is selected from Wherein said R is optionally further substituted by 0, 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, methyl, ethyl, methoxy or ethoxy ;
- R 1c is selected from OH, NH 2 , C 1-6 alkoxy, NHC 1-4 alkyl, or N(C 1-4 alkyl) 2 ;
- R 1c is selected from OH, NH 2 , C 1-4 alkoxy, NHC 1-4 alkyl, or N(C 1-4 alkyl) 2 ;
- R 1c is selected from OH, NH 2 , methoxy, ethoxy, NHCH 3 , N(CH 3 ) 2 ;
- each of R 4e and R 4f is independently selected from H, OH, -NR 1a R 1b , C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, or 5 to 12-membered heterocyclyl, wherein the heterocyclyl contains 1 to 4 heteroatoms selected from O, S or N;
- each of R 4e and R 4f is independently selected from H, OH, -NR 1a R 1b , C 1-4 alkyl, C 1-4 alkoxy or C 3-6 cycloalkyl, 5 to 10-membered heterocyclyl, wherein the heterocyclyl contains 1 to 4 heteroatoms selected from O, S or N;
- R 4e , R 4f are each independently selected from H, OH, NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, cyclopropyl, or cyclobutyl ;
- each R is independently selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl , pyrrolidinyl or phenyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetyl, azetidinyl, pyrrolidine
- each R is independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrole Alkyl, phenyl, -CH 2 -cyclopropyl or -CH 2 -cyclobutyl;
- R 8 , R 9 , or R 10 are each independently selected from H, F, Cl, Br, I, OH, cyano, CF 3 , NH 2 , methyl, or ethyl;
- R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-6 alkyl, hydroxy C 1-6 alkyl, cyano C 1-6 alkyl group or unsubstituted C 1-6 alkoxy group, and two R 7 and the carbon atom connected to it do not form a 3-6 membered heterocyclic group together, one of the following conditions must be met:
- X2 is selected from N;
- R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-4 alkyl, hydroxy C 1-4 alkyl, cyano C 1-4 alkyl group or unsubstituted C 1-4 alkoxy group, and two R 7 and the carbon atom connected to it do not form a 3-6 membered heterocyclic group together, one of the following conditions must be met:
- X2 is selected from N;
- the compound of general formula (I) is not a racemate as shown in the following compounds: And general formula (I)
- p is selected from 0, 1 or 2;
- n is selected from 0, 1 or 2;
- W is selected from O or S
- R 2 is selected from halogen, C 1-6 alkyl or C 1-6 alkoxy, wherein the alkyl, alkoxy are optionally further replaced by 0 to 4 selected from H, halogen, OH, cyano or NH 2 substituents are substituted;
- X 1 and X 2 are each independently selected from N or CR 3 ;
- Y is selected from NR 7 or C(R 7 ) 2 ;
- R 6 and R 7 at adjacent positions can form a double bond
- two R 6 and the atoms connected to them together form a C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally further replaced by 0 to 4 members selected from H , halogen, OH, O, cyano, NH 2 , C 1-6 alkyl, C 1-6 alkoxy, halogen substituted C 1-6 alkyl, hydroxy substituted C 1-6 alkyl, or C1-6 alkyl substituents substituted by cyano, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N;
- R 1c is selected from OH, NH 2 , C 1-6 alkoxy, NHC 1-4 alkyl or N(C 1-4 alkyl) 2 ;
- R is selected from C 5-12 carbocyclyl, 5 to 12 membered heterocyclyl, C 6-12 aryl or 5 to 12 membered heteroaryl, wherein the carbocyclyl, heterocyclyl, aryl or hetero Aryl is optionally further substituted by 0 to 4 R, wherein the heterocyclyl or heteroaryl contains 1 to 4 heteroatoms selected from O, S or N;
- R 4e , R 4f are each independently selected from H, OH, -NR 1a R 1b , C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl or 5 to 12 membered heterocyclyl, wherein said heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N;
- R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-6 alkyl, hydroxy C 1-6 alkyl, cyano C 1-6
- R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-6 alkyl, hydroxy C 1-6 alkyl, cyano C 1-6
- X 2 is selected from N.
- R 2 is selected from halogen, C 1-4 alkyl or C 1-4 alkoxy, wherein the alkyl and alkoxy are optionally further replaced by 0 to 4 selected from H, D, halogen, OH, cyano Or the substituent of NH 2 is substituted;
- X 1 and X 2 are each independently selected from N or CR 3 ;
- R 6 and R 7 at adjacent positions can form a double bond
- two R 6 and the atoms connected to them together form a C 3-6 cycloalkyl group or a 3-6 membered heterocyclic group, wherein the cycloalkyl group and heterocyclic group are optionally further selected from 0 to 4 H , halogen, OH, O, cyano, NH 2 , C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, cyano Substituents of C 1-4 alkyl substituted by radicals, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N;
- R 1c is selected from OH, NH 2 , C 1-4 alkoxy, NHC 1-4 alkyl or N(C 1-4 alkyl) 2 ;
- R is selected from C 5-7 monocyclic carbocyclyl, C 5-12 acyclic carbocyclyl, C 5-12 spirocyclic carbocyclyl, C 5-12 bridged ring carbocyclyl, 5-7 membered unit Ring heterocyclyl, 5 to 12 membered ring heterocyclyl, 5 to 12 membered spirocyclic heterocyclyl or 5 to 12 membered bridged ring heterocyclyl, C 6-10 aryl or 5 to 10 membered heteroaryl , wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or heteroaryl contains 1 to 4 selected from O, S or N heteroatoms;
- R 4e and R 4f are each independently selected from H, OH, -NR 1a R 1b , C 1-4 alkyl, C 1-4 alkoxy or C 3-6 cycloalkyl, 5 to 10 membered heterocyclyl, wherein said heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N;
- R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-4 alkyl, hydroxy C 1-4 alkyl, cyano C 1-4 alkane group or unsubstituted C 1-4 alkoxy group, and when two R 7 and the carbon atom connected to it do not form a 3-6 membered heterocyclic group together, one of the following conditions must be met:
- X 2 is selected from N.
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy or isopropoxy, wherein the methyl, ethyl , propyl, isopropyl, tert-butyl, methoxy, ethoxy or isopropoxy are optionally further replaced by 0 to 4 selected from H, D, F, Cl, Br, I, OH, cyano Or the substituent of NH 2 is substituted;
- R is selected from C 5-6 monocyclic carbocyclyl, C 5-10 acyclic carbocyclyl, C 5-11 spirocyclic carbocyclyl, C 5-12 bridged ring carbocyclyl, 5-6 membered unit Ring heterocyclyl, 5-10 membered ring heterocyclyl, 5-11 membered spirocyclic heterocyclyl, 5-12 membered bridged ring heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl , wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or heteroaryl contains 1 to 4 selected from O, S or N heteroatoms;
- R 4e , R 4f are each independently selected from H, OH, NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, cyclopropyl or cyclobutyl;
- R 8 , R 9 or R 10 are each independently selected from H, F, Cl, Br, I, OH, cyano, CF 3 , NH 2 , methyl or ethyl;
- each n is independently selected from 0, 1 or 2;
- R d are each independently selected from methyl, ethyl, propyl, isopropyl, t-butyl, methoxy, ethoxy, isopropoxy, the methyl, ethyl, propyl, isopropyl , tert-butyl, methoxy, ethoxy, and isopropoxy are further replaced by 1 to 3 selected from halogen, ethynyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkane C 2-4 alkenyl substituted by radical, C 2-4 alkynyl substituted by C 1-4 alkyl, C 1-4 alkoxy substituted by C 1-4 alkyloxy, C 1-4 alkoxy substituted by halogen Substituted by C 1-4 alkyl substituted by hydroxyl group, C 1-4 alkyl substituted by cyano group, C 3-6 cycloalkyl or 3 to 8 membered heterocyclic group;
- two R 6 and the atoms connected to it together form cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxetyl, oxanexyl, thiacyclopentyl , azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl;
- Each R is independently selected from cyclopentyl, cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidyl or naphthyl, said cyclopentyl, Cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidyl or naphthyl are optionally further substituted by 0 to 4 R 5 ;
- R 4 are each independently selected from
- R 4 are each independently selected from
- Each R 1 is independently selected from H, F, Cl, Br, I, OH, cyano, NH 2 , -OCD 3 , CD 3 , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy Base, ethoxy, isopropoxy, cyclopropyl, ethynyl, -CH 2 -cyclopropyl or -O-cyclopropyl;
- each R 1 is independently selected from -OCH 2 F, -OCHF 2 , -OCF 3 ,
- R are each independently selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl;
- R 2 are each independently selected from CD 3 , CHD 2 , CH 2 D;
- Each R3 is independently selected from H, methyl or ethyl
- Each R 1 is independently selected from H, F, Cl, Br, I, OH, cyano, NH 2 , -OCD 3 , CD 3 , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy Base, ethoxy, isopropoxy, cyclopropyl, ethynyl, -CH 2 -cyclopropyl or -O-cyclopropyl;
- each R 1 is independently selected from -OCH 2 F, -OCHF 2 , -OCF 3 ,
- R are each independently selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl;
- each R 2 is independently selected from CD 3 , CHD 2 , CH 2 D;
- Each R3 is independently selected from H, methyl or ethyl
- R 4 are each independently selected from
- R 6 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , methyl, ethyl, propyl, isopropyl;
- the compound represented by the aforementioned general formula (Id) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, generally Formula (Id) compound is selected from the compound shown in general formula (Id-1) or general formula (Id-2),
- R4 is selected from Wherein said R is optionally further substituted by 0, 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, C 1-4 alkyl, C 1-4 alkoxy replace;
- R 1 is selected from H, F, Cl, Br, I, -OCD 3 , CD 3 , C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, -CH 2 -C 3 -6 cycloalkyl or -OC 3-6 cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl are optionally further substituted by 0 to 4 F, ethynyl or propargyl;;
- R 2 is selected from F, Cl, Br, I, C 1-4 alkyl
- the compound represented by the aforementioned general formula (Id) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, generally Formula (Id) compound is selected from the compound shown in general formula (Id-1) or general formula (Id-2),
- R4 is selected from Wherein said R is optionally further substituted by 0, 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, methyl, ethyl, methoxy or ethoxy ;
- R 1 is selected from H, F, Cl, Br, I, -OCD 3 , CD 3 , methyl, ethyl, propyl, methoxy, ethoxy, isopropoxy, cyclopropyl, -CH 2 - cyclopropyl or -O-cyclopropyl;
- each R 1 is independently selected from -OCH 2 F, -OCHF 2 , -OCF 3 ,
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl;
- each R 2 is independently selected from CD 3 , CHD 2 , CH 2 D;
- the compound represented by the aforementioned general formula (I) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, generally Formula (I) compound is selected from the compound shown in general formula (Id-3), general formula (Id-4),
- R 7 is selected from C 2-4 alkynyl, C 3-6 carbocyclyl, 3-8 membered heterocyclyl
- X1 is selected from N or CH
- X2 is selected from N or CH, wherein the CH is optionally substituted by 1 methyl or ethyl group
- R 7 is selected from C 2-4 alkynyl, phenyl, C 3-6 cycloalkyl, 3-8 membered heterocycloalkyl or 5-6 membered heteroaryl
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, pyrrolidinyl, piperidinyl, Linyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazole base, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 ' is selected from H, F, OH, NH 2 , or substituted or un Substituted with one of the following groups: methyl, ethyl, propyl, isopropy
- Each R6 is independently selected from H, F, Cl, Br, CF3 , methyl or ethyl;
- R 1 , R 2 and R 4 are the same as those in the fifth embodiment of the present invention.
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, pyrrolidinyl, piperidinyl, Linyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazole base, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 ' is selected from H, F, OH, NH 2 , or substituted or un Substituted with one of the following groups: methyl, ethyl, propyl, isopropy
- R 1 , R 2 and R 4 are the same as those in the sixth embodiment of the present invention.
- the compound represented by the aforementioned general formula (Id-3), general formula (Id-4) or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salts or co-crystals is represented by the aforementioned general formula (Id-3), general formula (Id-4) or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salts or co-crystals,
- R4 is selected from Wherein said R is optionally substituted by 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, methyl, ethyl, methoxy or ethoxy;
- the compound represented by the following general formula (Id-5) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic is represented by the following general formula (Id-5) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic,
- R 1 is selected from -OCH 3 or -OCD 3 ;
- R 2 is selected from -CH 3 or -CD 3 ;
- n is selected from 1, 2 or 3.
- the compound represented by the following general formula (Id-6) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic is represented by the following general formula (Id-6) or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic,
- R 1 is selected from -OCH 3 or -OCD 3 ;
- R 2 is selected from -CH 3 or -CD 3 .
- R 1 is selected from -OCH 3 or -OCD 3 ;
- R 2 is selected from -CH 3 or -CD 3 .
- the compound of general formula (I) is selected from general formula (Id-3-a), general formula (Id-5-a), general formula (Id-6-a), general formula Compounds shown in formula (Id-7-a), general formula (Id-8-a),
- the present invention relates to a compound or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, wherein the compound is selected from one of the structures in Table E-1.
- R 1 is selected from R 1A .
- each R 1 is independently selected from H, F, Cl, Br, I, OH, cyano, NH 2 , methyl, ethyl, propyl, isopropyl, tert-butyl, methyl Oxygen, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, ethylthio, cyclopropyl, cyclobutyl or -WR 1d , wherein the methyl radical, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio,
- each R 1 is independently selected from H, F, Cl, Br, I, OH, cyano, NH 2 , methyl, ethyl, propyl, isopropyl, tert-butyl, methyl Oxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, ethylthio, cyclopropyl, cyclobutyl, -O-cyclopropyl, - O-cyclobutyl, -O-cyclopentyl, wherein the methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, acety
- each R is independently selected from H, F, Cl, Br, I, OH, cyano, NH 2 , -OCD 3 , CD 3 , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy radical, isopropoxy, cyclopropyl, ethynyl, -CH 2 -cyclopropyl or -O-cyclopropyl.
- R is selected from H, F, Cl, Br, I, -OCD 3 , CD 3 , methyl, ethyl, propyl, methoxy, ethoxy, isopropoxy, cyclopropyl, -CH 2 -cyclopropyl or -O-cyclopropyl.
- each R 1 is independently selected from -OCH 2 F, -OCHF 2 , -OCF 3 ,
- the present invention relates to some embodiments of general formula (Id-1), (Id-2), (Id-3), (Id-4)), R is selected from H, F, Cl, Br, I, - OCD 3 , CD 3 , C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, -CH 2 -C 3-6 cycloalkyl or -OC 3-6 cycloalkyl.
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), (Ic), (Id) or (Ie), W is selected from O or S.
- n is selected from 0,1,2.
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), X 1 and X 2 are each independently selected from N or CR 3 .
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), X 1 is selected from CR 3 , and X 2 is selected from CR 3 .
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), X 1 is selected from N, X 2 is selected from CR 3 .
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), X 1 is selected from CR 3 , and X 2 is selected from N.
- the present invention relates to some embodiments of general formula (I), (Ia), (Ib), X 1 and X 2 are each independently selected from N.
- Y is selected from NR 7 or C(R 7 ) 2 .
- Y is selected from NR 7A .
- Y is selected from C(R 7a ) 2 .
- the present invention relates to some embodiments of general formula (I), Y is selected from C(R 7B ) 2 .
- the present invention relates to some embodiments of general formula (I), selected from
- the present invention relates to some embodiments of the general formula (If), selected from
- each R3 is independently selected from H, methyl or ethyl.
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of Ie) or (If), R is selected from halogen, C 1-6 alkyl or C 1-6 alkoxy, wherein the alkyl and alkoxy are optionally further replaced by 0 to 4 Substituents selected from H, D, halogen, OH, cyano or NH2 .
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of Ie) or (If), R is selected from halogen, C 1-4 alkyl or C 1-4 alkoxy, wherein the alkyl and alkoxy are optionally further replaced by 0 to 4 Substituents selected from H, D, halogen, OH, cyano or NH2 .
- R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy or iso Propoxy, wherein the methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy or isopropoxy are optionally further replaced by 0 to 4 selected from H, D, Substituents of F, Cl, Br, I, OH, cyano or NH2 .
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy or iso Propoxy.
- each R is independently selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl.
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R is selected from F, Cl, Br, I, methyl, ethyl, propyl, isopropyl.
- each R 2 is independently selected from CD 3 , CHD 2 , CH 2 D.
- the present invention relates to some embodiments of general formula (Id-1), (Id-2), R 2 is selected from F, Cl, Br, I, C 1-4 alkyl.
- each R 6 is independently selected from H, halogen, OH, -NR 1a R 1b , C 1-6 alkyl or C 1-6 alkoxy, wherein the alkyl , alkoxy is optionally further substituted by 0 to 4 C 1- 6 alkyl, C 1-6 alkyl substituted by hydroxy, C 1-6 alkyl substituted by cyano, C 3-6 cycloalkyl or a substituent of 3 to 8 membered heterocyclic group, wherein the hetero Cyclic groups contain 1 to 4 heteroatoms selected from O, S or N.
- each R 6 is independently selected from H, halogen, OH, -NR 1a R 1b , C 1-4 alkyl or C 1-4 alkoxy, wherein the alkyl , alkoxy is optionally further substituted by 0 to 4 C 1- 4 alkyl, C 1-4 alkyl substituted by hydroxy, C 1-4 alkyl substituted by cyano, C 3-6 cycloalkyl or 3 to 8 membered heterocyclic group, wherein the hetero Cyclic groups contain 1 to 4 heteroatoms selected from O, S or N.
- each R is independently selected from H, F, Cl, Br, I, OH, NH 2 , methyl, ethyl, propyl, isopropyl, tert-butyl, Methoxy, Ethoxy or Isopropoxy.
- each R 6 is independently selected from H, F, Cl, Br, I, OH, NH 2 , methyl, ethyl, propyl, isopropyl.
- R is selected from H.
- R 7 is selected from R 7A , R 7B or R 7a .
- R 7 is selected from R 7' .
- R is selected from H, methoxymethyl, methoxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, nitrogen Butyl, azocyclopentyl, azacyclohexyl, oxetanyl, oxolyl, oxetanyl.
- the present invention relates to some embodiments of the general formula (Id-2), 2 R 7B together with the carbon to which they are attached form a ring as follows:
- R 7 is selected from methoxymethyl, methoxyethyl, C 2-4 alkynyl, C 3-6 cycloalkyl or 4 to 7 member heterocycle,.
- the present invention relates to some embodiments of the general formula (Id-2), 2 R 7B together with the carbon to which they are attached form a 4-7 membered heterocycle (preferably a 4-6 membered heterocycle) as follows.
- each R d is independently selected from methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy
- the methyl, ethyl, propyl, isopropyl, t-butyl, methoxy, ethoxy, and isopropoxy groups are further replaced by 1 to 3 selected from halogen, ethynyl, and C2-4 alkynyl , C 1-4 alkoxy, C 1-4 alkyl substituted C 2-4 alkenyl, C 1-4 alkyl substituted C 2-4 alkynyl, C 1-4 alkyloxy substituted C 1 -4 alkoxy, halogen substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl , cyano substituted C 1-4 alkyl, C 3-6 cycloalkyl or 3 to 8 membered hetero
- each R d is independently selected from methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy
- the methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, and isopropoxy groups are further replaced by 1 to 3 selected from F, Cl, Br, I, ethynyl, Substituents of methoxy, ethoxy, CF 3 , -CH 2 F, cyclopropyl, cyclobutyl, azetidinyl or pyrrolidinyl.
- the present invention relates to general formula (I), (Id), (Id-1), (Id-2), in some embodiments, two R 7 form 3-6 membered heterocyclyl together with the carbon atom that it is attached to,
- the present invention relates to some embodiments of general formula (I) or (Ib), R 6 and R 7 at adjacent positions may form a double bond.
- the present invention relates to some embodiments of the general formula (I) or (Id), two R 6 and the atoms connected to it together form cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxolane , oxanyl, thiolanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl.
- the present invention relates to some embodiments of general formula (I), selected from Denotes a single or double bond, with only one double bond in it.
- the present invention relates to some embodiments of general formula (I), selected from Its upper part is connected with R4 .
- each R 6 is independently selected from H, F, Cl, Br, CF 3 , methyl, ethyl.
- R 7 is selected from C 2-4 alkynyl, C 3-6 carbocyclyl, 3 to 8 membered heterocyclyl
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl , azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, Furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 ' Selected from H, F, OH, NH 2 , or one of the following substituted or unsubstituted
- R 7 is selected from one of substituted or unsubstituted following groups: ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl , azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxetanyl, oxolyl, oxanyl, pyrazolyl, pyrrolyl, imidazolyl, Furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, 1,2,4-oxadiazolyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, R 7 ' Selected from H, F, OH, NH 2 , or one of the following substituted or unsubstituted
- OH, O, cyano, NH 2 , methyl, ethyl, methoxy, ethoxy, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, Substituents of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl.
- R is selected from ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, wherein said propynyl, Propargyl, cyclopropyl, cyclobutyl, cyclopentyl are optionally further replaced by 0 to 4 selected from H, D, F, Cl, Br, CF 3 , OH, methyl, ethyl, methoxy, Ethoxy, cyclopropyl substituents, R 7 'is selected from H, F, OH, NH 2 , methyl, ethyl, methoxy, ethoxy, wherein the methyl, ethyl, Methoxy and ethoxy are optionally further substituted by 0 to 4 substituents selected from H, D, F, Cl, Br, CF 3 , OH, methyl, ethyl, methoxy
- the present invention relates to some embodiments of general formula (Id-3), (Id-4), X 1 is selected from N or CH, X 2 is selected from N or CH, wherein said CH is optionally replaced by 1 methyl or Ethyl substitution.
- the present invention relates to some embodiments of general formula (Id-3), (Id-4), X 1 is selected from CH, and X 2 is selected from CH.
- R is selected from C 5-12 carbocyclyl, 5-12 membered heterocyclyl, C 6-12 aryl or 5-12 membered heteroaryl, wherein said Carbocyclyl, heterocyclyl, aryl or heteroaryl are optionally further substituted by 0 to 4 R, wherein said heterocyclyl or heteroaryl contains 1 to 4 heterocyclyls selected from O, S or N atom.
- R 4 is selected from C 5-7 monocyclic carbocyclyl, C 5-12 acyclic carbocyclyl, C 5-12 spirocyclic carbocyclyl, C 5-12 Member bridged ring carbocyclyl, 5 to 7 membered monocyclic heterocyclyl, 5 to 12 membered ring heterocyclyl, 5 to 12 membered spirocyclic heterocyclyl or 5 to 12 membered bridged ring heterocyclyl, C 6 -10 aryl or 5 to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or Heteroaryl contains 1 to 4 heteroatoms selected from O
- R 4 is selected from C 5-6 monocyclic carbocyclyl, C 5-10 acyclic carbocyclyl, C 5-11 spirocyclic carbocyclyl, C 5-12 Member bridged ring carbocyclyl, 5 to 6 membered monocyclic heterocyclyl, 5 to 10 membered ring heterocyclyl, 5 to 11 membered spirocyclic heterocyclyl, 5 to 12 membered bridged ring heterocyclyl, C 6 -10 aryl or 5 to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by 0 to 4 R 5 , wherein the heterocyclyl or Heteroaryl contains 1 to 4 heteroatoms selected from O
- each R is independently selected from cyclopentyl, cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidine Base or naphthyridyl, said cyclopentyl, cyclohexyl, benzocyclohexyl, benzocyclopentyl, phenyl, naphthyl, pyridyl, pyrazolyl, pyrimidyl or naphthyl are optionally further replaced by 0 to 4 R 5 substitutions.
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), each R is independently selected from
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), each R is independently selected from
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R is selected from Wherein said R is optionally further substituted by 0, 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, methyl, ethyl, methoxy or ethoxy .
- the present invention relates to some embodiments of general formula (Id-1), (Id-2), (Id-3), (Id-4), R is selected from Wherein said R is optionally further substituted by 0, 1, 2 or 3 substituents selected from F, Cl, Br, I, OH, cyano, C 1-4 alkyl, C 1-4 alkoxy replace.
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R 1c is selected from OH, NH 2 , C 1-6 alkoxy, NHC 1-4 alkyl or N(C 1-4 alkyl) 2 .
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R 1c is selected from OH, NH 2 , C 1-4 alkoxy, NHC 1-4 alkyl or N(C 1-4 alkyl) 2 .
- the present invention relates to general formula (I), (Ia), (Ib), (Ic), (Id), (Id-1), (Id-2), (Id-3), (Id-4), ( In some embodiments of le) or (If), R 1c is selected from OH, NH 2 , methoxy, ethoxy, NHCH 3 , N(CH 3 ) 2 .
- R 4c and R 4d are each independently selected from H, OH, C 1-4 alkyl, C 1-4 alkoxy, -NR 1a R 1b , -OR 1d , C 3-6 carbocyclyl, 4 to 8 membered heterocyclyl, C 6-10 aryl or 5 to 10 membered heteroaryl, wherein the alkyl, alkoxy, carbocyclyl, heterocyclyl, aryl radical or heteroaryl is optionally substituted by 0 to 4 C 1- 4 alkyl, C 1-4 alkyl substituted by hydroxy, C 1-4 alkyl substituted by cyano, C 3-6 cycloalkyl or 3 to 8 membered heterocyclic group, wherein the hetero Cyclic group, heteroaryl group contains 1 to 4
- R 4e and R 4f are each independently selected from H, OH, -NR 1a R 1b , C 1-6 alkyl, C 1-6 alkoxy, C 3-8 Cycloalkyl or 5 to 12 membered heterocyclyl, wherein said heterocyclyl contains 1 to 4 heteroatoms selected from O, S or N.
- R 4e and R 4f are each independently selected from H, OH, -NR 1a R 1b , C 1-4 alkyl, C 1-4 alkoxy or C 3-6 Cycloalkyl, 5- to 10-membered heterocyclic group, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S or N.
- R 4e and R 4f are each independently selected from H, OH, NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, ring Propyl or cyclobutyl.
- each R 1d is independently selected from H, C 1-6 alkyl, C 3-8 carbocyclyl or 4 to 10 membered heterocyclyl, wherein the alkyl, carbon
- each R 1d is independently selected from H, C 1-4 alkyl, C 3-6 carbocyclyl or 4 to 8 membered heterocyclyl, wherein the alkyl, carbon
- each R 1d is independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, nitrogen Heterocyclobutyl, pyrrolidinyl, phenyl, -CH 2 -cyclopropyl or -CH 2 -cyclobutyl.
- R 8 , R 9 or R 10 are each independently selected from H, F, Cl, Br, I, OH, cyano, CF 3 , NH 2 , methyl, ethyl.
- R 1a , R 1b are each independently selected from H, methyl, ethyl, propyl or isopropyl, wherein the methyl, ethyl, propyl or isopropyl
- the present invention relates to some embodiments of general formula (I), when Y is selected from C(R 7 ) 2 , R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-6 alkyl, hydroxyl C 1-6 alkyl, cyano C 1-6 alkyl or unsubstituted C 1-6 alkoxy, and when two R 7 and the carbon atoms connected to them do not form a 3-6 membered heterocyclic group together, One of the following conditions must be met:
- X 2 is selected from N.
- the present invention relates to some embodiments of general formula (I), when Y is selected from C(R 7 ) 2 , R 7 is selected from H, OH, -NR 1a R 1b , unsubstituted C 1-4 alkyl, hydroxyl C 1-4 alkyl, cyano C 1-4 alkyl or unsubstituted C 1-4 alkoxy, and when two R 7 and the carbon atoms connected to them do not form a 3-6 membered heterocyclic group together, One of the following conditions must be met:
- X 2 is selected from N.
- the present invention relates to a pharmaceutical composition, comprising the compound described in the present invention or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, and pharmaceutically acceptable Accepted carrier.
- the present invention relates to a compound of the present invention or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal or the pharmaceutical composition or drug of the present invention
- the present invention relates to a pharmaceutical composition or pharmaceutical preparation, wherein the pharmaceutical composition or pharmaceutical preparation comprises a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, metabolite , a pharmaceutically acceptable salt or co-crystal and a pharmaceutically acceptable excipient.
- the pharmaceutical composition may be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as "preparation specification").
- the present invention also provides a method for treating a disease in a mammal, which comprises administering to the mammal a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, Metabolites, pharmaceutically acceptable salts or co-crystals or pharmaceutical compositions.
- the mammals of the present invention include humans.
- Effective amount or “therapeutically effective amount” as used in the present application refers to the administration of a sufficient amount of the compound disclosed in the present application, which will relieve one or more of the diseases or conditions (such as kidney disease) to be treated to some extent. Various symptoms. In some embodiments, the result is reduction and/or alleviation of signs, symptoms or causes of disease, or any other desired alteration of a biological system.
- an "effective amount” for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.
- therapeutically effective amounts include, but are not limited to, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40 -600mg, 50-600mg, 60-600mg, 70-600mg, 75-600mg, 80-600mg, 90-600mg, 100-600mg, 200-600mg, 1-500mg, 2-500mg, 3-500mg, 4-500mg , 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg, 80-500mg, 90 -500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg,
- the pharmaceutical composition includes but is not limited to 1-600mg, 20-400mg, 25-200mg, 1mg, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 110mg, 120mg, 125mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 300mg
- the pharmaceutical composition can be formulated for a specific route of administration, such as oral administration, parenteral administration, rectal administration, and the like.
- the pharmaceutical composition of the present invention can be prepared in solid form (including but not limited to capsules, tablets, pills, granules, powders or suppositories) or in liquid form (including but not limited to solutions, suspensions or emulsions).
- a method for treating a disease in a mammal comprising administering to a subject a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal, the therapeutically effective amount is preferably 1-600 mg, wherein the disease is preferably kidney disease.
- a method for treating a disease in a mammal comprises, the compound of the present invention or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal with A daily dose of 1-800 mg/day is administered to the subject, and the daily dose can be a single dose or divided doses.
- the daily dose includes but is not limited to 10-800 mg/day, 25-800 mg/day, 50 - 800 mg/day, 100-800 mg/day, 200-800 mg/day, 25-400 mg/day, 50-400 mg/day, 100-400 mg/day, 200-400 mg/day, in some embodiments, the daily dosage comprises But not limited to 10mg/day, 20mg/day, 25mg/day, 50mg/day, 100mg/day, 125mg/day, 150mg/day, 200mg/day, 400mg/day, 600mg/day, 800mg/day.
- the present invention relates to a kit, which may comprise a composition in single or multi-dose form, the kit comprising a compound of the present invention or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutical acceptable salt or co-crystal, the compound of the present invention or its stereoisomer, deuterium, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal amount and its amount in the above-mentioned pharmaceutical composition same.
- the carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, and I involved in the groups and compounds of the present invention include their isotopes, and the carbon involved in the groups and compounds of the present invention , hydrogen, oxygen, sulfur or nitrogen are optionally further replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C, 13 C and 14 C, and the isotopes of hydrogen include protium (H), deuterium (D, Also called heavy hydrogen), tritium (T, also called super heavy hydrogen), oxygen isotopes include 16 O, 17 O and 18 O, sulfur isotopes include 32 S, 33 S, 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, the isotopes of fluorine include 17 F and 19 F, the isotopes of chlorine include 35 Cl and 37 Cl, and the isotopes of bromine include 79 Br and 81 Br.
- the isotopes of carbon include 12 C, 13 C and 14
- Halogen means F, Cl, Br or I.
- Halogen substituted refers to F, Cl, Br or I substitution, including but not limited to 1 to 10 substituents selected from F, Cl, Br or I, 1 to 6 substituents selected from F, Cl, Br Or substituted by a substituent of I, substituted by 1 to 4 substituents selected from F, Cl, Br or I.
- Halo-substituted is simply referred to as "halo”.
- Alkyl refers to a substituted or unsubstituted linear or branched saturated aliphatic hydrocarbon group, including but not limited to an alkyl group of 1 to 20 carbon atoms, an alkyl group of 1 to 8 carbon atoms, an alkyl group of 1 to 6 An alkyl group of carbon atoms, an alkyl group of 1 to 4 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and its various branched isomers.
- Alkyl groups appearing herein are defined in accordance with this definition. Alkyl groups can be monovalent, divalent, trivalent or tetravalent.
- Heteroalkyl refers to a substituted or unsubstituted alkyl group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S) replace.
- Non-limiting examples include -X(CH 2 )vX(CH 2 )vX(CH 2 )vH (v is an integer from 1 to 5, each of X is independently selected from a bond or a heteroatom, and the heteroatom includes but is not limited to N, O or S, and at least one X is selected from heteroatoms, and N or S in heteroatoms can be oxidized into various oxidation states).
- Heteroalkyl groups can be monovalent, divalent, trivalent or tetravalent.
- Alkylene refers to substituted or unsubstituted linear and branched divalent saturated hydrocarbon groups, including -(CH 2 ) v - (v is an integer from 1 to 10), examples of alkylene include but not Limited to methylene, ethylene, propylene and butylene, etc.
- Heteroalkylene means a substituted or unsubstituted alkylene group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S) substitutions.
- Non-limiting examples include -X(CH 2 )vX(CH 2 )vX(CH 2 )v-, v is an integer from 1 to 5, each of X is independently selected from a bond, N, O or S, and at least 1 Each X is selected from N, O or S.
- Cycloalkyl means a substituted or unsubstituted saturated carbocyclic hydrocarbon group, usually having 3 to 10 carbon atoms, non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclo Heptyl etc. As used herein, cycloalkyl is as defined above. Cycloalkyl groups can be monovalent, divalent, trivalent or tetravalent.
- Heterocycloalkyl refers to a substituted or unsubstituted saturated heteroatom-containing cyclic hydrocarbon group, including but not limited to 3 to 10 atoms, 3 to 8 atoms, containing 1 to 3 atoms selected from N, O or
- the heteroatoms of S, the selectively substituted N and S in the ring of heterocycloalkyl can be oxidized into various oxidation states.
- the heterocycloalkyl group can be connected to a heteroatom or a carbon atom, the heterocycloalkyl group can be connected to an aromatic ring or a non-aromatic ring, and the heterocycloalkyl group can be connected to a bridged ring or a spiro ring.
- Non-limiting examples include ring Oxyethyl, aziridyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydro-2H-pyranyl, dioxolanyl, dioxanyl, pyrrolidinyl, Piperidinyl, imidazolidinyl, oxazolidinyl, oxazinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl.
- a heterocycloalkyl group can be monovalent, divalent, trivalent or tetravalent.
- alkenyl means a substituted or unsubstituted straight and branched unsaturated hydrocarbon group having at least 1, usually 1, 2 or 3 carbon-carbon double bonds, the main chain including but not limited to 2 to 10 1, 2 to 6, or 2 to 4 carbon atoms
- alkenyl examples include but are not limited to vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl , 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-but Alkenyl, 2-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1 -pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octen
- Alkynyl means a substituted or unsubstituted straight and branched monovalent unsaturated hydrocarbon group having at least 1, usually 1, 2 or 3 carbon-carbon triple bonds, the main chain comprising 2 to 10 Carbon atoms, including but not limited to 2 to 6 carbon atoms in the main chain, 2 to 4 carbon atoms in the main chain, alkynyl examples include but not limited to ethynyl, propargyl, 1-propynyl , 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1 -Methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl,
- Alkoxy means a substituted or unsubstituted -O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexyloxy, cyclopropyl Oxygen and Cyclobutoxy.
- Carbocyclyl or “carbocycle” refers to a substituted or unsubstituted aromatic ring or a substituted or unsubstituted saturated or unsaturated non-aromatic ring, and the aromatic ring or non-aromatic ring can be a 3- to 8-membered unit Ring, 4 to 12 membered bicyclic ring or 10 to 15 membered tricyclic ring system, the carbocyclic group can be connected to an aromatic ring or a non-aromatic ring, and the aromatic ring or non-aromatic ring is optionally a monocyclic ring, a bridged ring or a spiro ring.
- Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-enyl, 1-cyclopentyl Pentyl-3-enyl, cyclohexyl, 1-cyclohexyl-2-enyl, 1-cyclohexyl-3-enyl, cyclohexenyl, benzene ring, naphthalene ring,
- a "carbocyclyl” or “carbocycle” can be monovalent, divalent, trivalent or tetravalent.
- Heterocyclic group or “heterocyclic ring” refers to a substituted or unsubstituted aromatic ring or a substituted or unsubstituted saturated or unsaturated non-aromatic ring.
- the aromatic ring or non-aromatic ring can be a 3- to 8-membered unit Ring, 4 to 12 membered bicyclic ring or 10 to 15 membered tricyclic ring system, and contains 1 or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S, hetero
- the selectively substituted N and S in the ring of the cyclic group can be oxidized into various oxidation states.
- the heterocyclic group can be connected to a heteroatom or a carbon atom, the heterocyclic group can be connected to an aromatic ring or a non-aromatic ring, and the heterocyclic group can be connected to a bridged ring or a spiro ring.
- Non-limiting examples include oxirane , aziridyl, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxanyl, nitrogen Heterocycloheptyl, pyridyl, furyl, thienyl, pyryl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorph Linyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiapentanyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl Base, benzimidazolyl, benzo
- Spiro ring or “spirocyclic group” refers to a polycyclic group that shares one atom (called spiro atom) between substituted or unsubstituted monocyclic rings.
- a “spirocycle” or “spirocyclyl” can be monovalent, divalent, trivalent or tetravalent.
- the number of ring atoms in the double ring system includes but is not limited to 5 to 20, 5 to 14, 5 to 12, and 5 to 10.
- Non-limiting examples include: "Alkyl” or “alkyl” may be monovalent, divalent, trivalent or tetravalent.
- the number of ring atoms includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12 or 5 to 10.
- Non-limiting examples include
- a "bridged ring” or “bridged ring group” may be monovalent, divalent, trivalent or tetravalent.
- Carbospiro refers to a “spirocycle” whose ring system consists only of carbon atoms.
- the definitions of “carbospirocycle”, “spirocyclic carbocyclyl”, “spirocarbocyclyl” or “carbospirocyclyl” appearing herein are consistent with spirocycle.
- Carbocyclic “paracyclic carbocyclyl”, “paracarbocyclyl” or “carbocyclyl” refers to a “carbocyclyl” whose ring system consists only of carbon atoms.
- the definition of “carbocyclyl”, “paracyclic carbocyclyl”, “paracarbocyclyl” or “carbocyclyl” used herein is consistent with that of paracyclyl.
- Carbobridged ring refers to a “bridged ring” whose ring system consists only of carbon atoms.
- the definitions of "carbon bridged ring”, “bridged ring carbocyclyl”, “bridged carbocyclyl” or “carbobridged ring” appearing in this article are consistent with those of bridged ring.
- Heterocyclic group refers to the “heterocyclic group” or “heterocyclic group” of a monocyclic ring system, and the heterocyclic group, "monocyclic heterocyclic group” appearing herein group” or “heteromonocyclic group”, the definition of which is consistent with that of heterocycle.
- Heterocyclyl refers to “heterocycles” that contain heteroatoms.
- the definition of heterocyclic ring, “heterocyclic group”, “heterocyclic heterocyclic group” or “heterocyclic group” used herein is consistent with that of parallel ring.
- Heterospiro refers to a “spirocycle” that contains heteroatoms.
- heterospirocycle refers to a “spirocycle” that contains heteroatoms.
- heterospirocycle refers to a “spirocycle” that contains heteroatoms.
- heterospirocycle refers to a “spirocycle” that contains heteroatoms.
- heterospirocycle refers to a “spirocycle” that contains heteroatoms.
- heterospirocycle refers to a "heterospirocyclyl” that contains heteroatoms.
- Heterobridged ring refers to a “bridged ring” that contains heteroatoms.
- the definition of heterobridged ring, “heterobridged ring group”, “bridged ring heterocyclyl group” or “heterobridged ring group” used herein is consistent with bridged ring.
- Aryl or “aromatic ring” refers to a substituted or unsubstituted aromatic hydrocarbon group with a single ring or a condensed ring, and the number of ring atoms in the aromatic ring includes but is not limited to 6 to 18, 6 to 12 or 6 to 10 carbon atoms.
- the aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring bonded to the parent structure is an aryl ring, non-limiting examples include benzene, naphthalene, "Aryl” or “aromatic ring” may be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.
- heteroaryl examples include, but are not limited to, pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, Benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc.
- the heteroaryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring bonded to the parent structure is a heteroaryl ring, non-limiting examples include Where heteroaryl appears herein, its definition is consistent with this definition.
- Heteroaryl groups can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the heteroaryl ring.
- 5-membered ring and 5-membered heteroaromatic ring refers to a 5-membered condensed heteroaromatic ring, at least one of the two rings contains more than one heteroatom (including but not limited to O, S or N), the entire group is aromatic, and non-limiting examples include pyrrolopyrrole ring, pyrazolopyrrole ring, pyrazolopyrazole ring, pyrrolopyrrole ring, pyrazolofuran ring, pyrrolothiophene ring, pyrazolothiophene ring.
- 5 and 6-membered heteroaryl ring refers to a 5-6 membered fused heteroaryl ring, at least one of the two rings contains more than one heteroatom (including but not limited to O, S or N) , the entire group is aromatic, non-limiting examples include benzo 5-membered heteroaryl, 6-membered heteroaryl and 5-membered heteroaryl.
- Constants 1 to 5 heteroatoms selected from O, S or N means containing 1, 2, 3, 4 or 5 heteroatoms selected from O, S or N.
- Substituted by 0 to X substituents means substituted by 0, 1, 2, 3...X substituents, X is selected from any integer between 1 and 10.
- substituted by 0 to 4 substituents means substituted by 0, 1, 2, 3 or 4 substituents.
- substituted by 0 to 5 substituents means substituted by 0, 1, 2, 3, 4 or 5 substituents.
- the heterobridged ring is optionally further substituted by 0 to 4 substituents selected from H or F means that the heterobridged ring is optionally further substituted by 0, 1, 2, 3 or 4 substituents selected from H or F base replaced.
- X-Y-membered rings (X is selected from integers less than Y and greater than 3, Y is selected from any integer between 4 and 12) including X+1, X+2, X+3, X+4...Y-membered rings .
- Rings include heterocycles, carbocycles, aryls, aryls, heteroaryls, cycloalkyls, heteromonocycles, heteroheterocycles, heterospirocycles or heterobridged rings.
- 4--7 membered heteromonocyclic ring refers to 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring
- 5--10-membered heterocyclic ring refers to 5-, 6-, 7-, and 8-membered heterocyclic rings. , 9- or 10-membered heterocyclic rings.
- Alkyl optionally substituted by F means that the alkyl group may but not necessarily be substituted by F, and the description includes the case where the alkyl group is substituted by F and the case where the alkyl group is not substituted by F.
- “Pharmaceutically acceptable salt” or “pharmaceutically acceptable salt thereof” means that the compound of the present invention maintains the biological effectiveness and characteristics of free acid or free base, and the free acid is mixed with a non-toxic inorganic base or Organic bases, wherein the free bases are salts obtained by reacting with non-toxic inorganic acids or organic acids.
- “Pharmaceutical composition” refers to one or more compounds of the present invention, or their stereoisomers, tautomers, deuterated products, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or A mixture of co-crystals and other chemical components, wherein “other chemical components” refer to pharmaceutically acceptable carriers, excipients and/or one or more other therapeutic agents.
- Carrier refers to a material that does not produce significant irritation to an organism and that does not abrogate the biological activity and properties of the administered compound.
- Excipient refers to an inert substance added to a pharmaceutical composition to facilitate administration of the compound.
- Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders agents and disintegrants.
- Preparation specification refers to the weight of the main drug contained in each tube, tablet or other unit preparation.
- Prodrug refers to a compound of the present invention that can be transformed into a biologically active compound through in vivo metabolism.
- the prodrugs of the present invention are prepared by modifying the amino or carboxyl groups of the compounds of the present invention, which modifications can be removed by routine manipulation or in vivo to obtain the parent compound.
- the prodrugs of the present invention are administered to a mammalian subject, the prodrugs are cleaved to form free amino or carboxyl groups.
- Co-crystal refers to the crystal formed by the combination of active pharmaceutical ingredient (API) and co-crystal former (CCF) under the action of hydrogen bonding or other non-covalent bonds, wherein the pure state of API and CCF are both solid, and there is a fixed stoichiometric ratio between the components.
- a co-crystal is a multi-component crystal, including both a binary co-crystal formed between two neutral solids and a multi-element co-crystal formed between a neutral solid and a salt or solvate.
- Animal is meant to include mammals such as humans, companion animals, zoo animals and domestic animals, preferably humans, horses or dogs.
- Stepoisomer refers to isomers produced by different arrangements of atoms in a molecule in space, including cis-trans isomers, enantiomers and conformational isomers.
- Tautomer refers to a functional group isomer produced by a certain atom in a molecule moving rapidly at two positions, such as keto-enol isomerization and amide-imino alcohol isomerization.
- IC50 is the concentration of drug or inhibitor required to inhibit a given biological process (or some component of the process such as an enzyme, receptor, cell, etc.) by half.
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- HPLC HPLC-based high pressure liquid chromatography
- the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
- the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm-0.20mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm. -0.5mm;
- the known starting materials of the present invention can be used or synthesized according to methods known in the art, or can be purchased from Titan Technology, Anaiji Chemical, Shanghai Demo, Chengdu Kelon Chemical, Shaoyuan Chemical Technology, Bailingwei Technology, etc. company.
- Tf trifluoromethanesulfonyl. Boc: tert-butoxycarbonyl. Ts: p-toluenesulfonyl. Cbz: benzyloxycarbonyl.
- DMA dimethylacetamide
- Solutol polyethylene glycol-15-hydroxystearate
- Saline normal saline
- MC methylcellulose solution
- the fifth step 4-((2S,4S)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-4-(methoxymethyl) Trifluoroacetate of piperidin-2-yl)benzoic acid (compound 1-A)
- Trifluoroacetic acid salt of compound 1 was separated and prepared by high performance liquid chromatography to obtain trifluoroacetic acid salt of compound 1-a and 1-b.
- Compound 1-a or Compound 1-b is one of the isomers of Compound 1-A or Compound 1-B, respectively.
- Step 1 Methyl 4-((2S)-4-hydroxy-4-(3-hydroxypropyl)piperidin-2-yl)benzoate [2c-a (diastereomer 1)]
- (2S)-4-Hydroxy-4-(3-hydroxypropyl)-2-(4-(methoxycarbonyl)phenyl)piperidine-1-carboxylic acid tert-butyl ester [2d-a(diastereo Body 1)] (0.650g, 1.65mmol) was dissolved in 10mL of dichloromethane, followed by adding triethylamine (0.501g, 4.95mmol) and DMAP (0.020g, 0.164mmol), then adding p-toluenesulfonyl chloride (0.629g , 3.30mmol), and reacted at room temperature for 16h after the addition was completed.
- Step 4 Hydrochloride of methyl 4-[(7S)-1-oxa-8-azaspiro[4.5]dec-7-yl]benzoate [2f-a (diastereomer 1)]
- the fifth step 5-methoxy-4-(((7S)-7-(4-(methoxycarbonyl)phenyl)-1-oxa-8-azaspiro[4.5]decane-8- yl)methyl)-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester [2g-a (diastereomer 1)]
- reaction liquid was cooled to room temperature, 10 mL of tetrahydrofuran, 2 mL of water and 2 mL of methanol were added in sequence, and then lithium hydroxide monohydrate (0.120 g, 2.9 mmol) was added, and reacted at room temperature for 16 h.
- Preparation method Dissolve the crude product in methanol and dimethyl sulfoxide, and filter it with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/water (containing 0.1% TFA).
- Gradient elution method acetonitrile was eluted by 5% gradient to 60% (elution time 15min), and lyophilized to obtain 4-((7S)-8-((5-methoxyl-7-methyl-1H-indole -4-yl)methyl)-1-oxa-8-azaspiro[4.5]dec-7-yl)benzoic acid [compound 2-a (diastereomer 1)] trifluoroacetate salt ( 0.100g).
- Compound 2-a (Diastereomer 1) is one of the isomers of Compound 2-A or Compound 2-B.
- Step 1 Methyl 4-((2S)-4-hydroxy-4-(3-hydroxypropyl)piperidin-2-yl)benzoate [2c-b (diastereomer 2)]
- (2S)-4-Hydroxy-4-(3-hydroxypropyl)-2-(4-(methoxycarbonyl)phenyl)piperidine-1-carboxylic acid tert-butyl ester [2d-b (diastereo Body 2)] (0.320g, 0.81mmol) was dissolved in 10mL of dichloromethane, triethylamine (0.250g, 2.47mmol) and DMAP (0.010g, 0.0820mmol) were added successively, and p-toluenesulfonyl chloride (0.310g , 1.63mmol), and reacted at room temperature for 16h after the addition was completed.
- the fifth step 5-methoxy-4-(((7S)-7-(4-(methoxycarbonyl)phenyl)-1-oxa-8-azaspiro[4.5]decane-8- base)methyl)-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester [2g-b (diastereomer 2)]
- reaction solution was cooled to room temperature, 10 mL of tetrahydrofuran, 2 mL of water and 2 mL of methanol were added in sequence, and then lithium hydroxide monohydrate (0.067 g, 1.6 mmol) was added, and reacted at room temperature for 16 h.
- Preparation method Dissolve the crude product in methanol and dimethyl sulfoxide, and filter it with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/water (containing 0.1% TFA).
- Gradient elution method acetonitrile was eluted by 5% gradient to 60% (elution time 15min), and lyophilized to obtain 4-((7S)-8-((5-methoxyl-7-methyl-1H-indole -4-yl)methyl)-1-oxa-8-azaspiro[4.5]dec-7-yl)benzoic acid [compound 2-b (diastereomer 2)] trifluoroacetate ( 0.045g).
- Compound 2-b (diastereomer 2) is one of the isomers of compound 2-A or compound 2-B.
- the second step the maleate salt of 2-methoxyethyl 4-[(2S,4S)-4-(2-methoxyethoxy)piperidin-2-yl]benzoate (3c)
- (2S,4S)-4-(2-methoxyethoxy)-2-(4-((2-methoxyethoxy)carbonyl)phenyl)piperidine-1-carboxylic acid benzyl ester ( 3b) (0.180g, 0.382mmol) was dissolved in 5mL of methanol, 30mg of 10% palladium on carbon was added, and the mixture was reacted at room temperature under a hydrogen balloon atmosphere for 2h.
- the maleate (0.173 g) Dissolve in 10 mL of absolute ethanol, add tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate (0.140 g, 0.484 mmol) (see WO2015009616 for the synthesis method ), replace the nitrogen three times, add 5mg Ir(CO) 2 acac, replace the hydrogen three times, raise the temperature to 75°C, and place it in a hydrogen balloon atmosphere to react for 24h.
- Preparation method Dissolve the crude product in methanol and dimethyl sulfoxide, and filter it with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/water (containing 0.1% TFA).
- the reaction system was filtered under reduced pressure, and the filtrate was concentrated under reduced pressure to obtain a crude product (320 mg).
- the above crude product (320 mg) was dissolved in 10 mL of isopropyl acetate, maleic acid (77 mg, 0.66 mmol) was added, and stirred at room temperature for 16 h.
- the reaction system was concentrated under reduced pressure to obtain the maleic acid of the crude product 4-((2S,4S)-4-(cyclopropylmethoxy)piperidin-2-yl)cyclopropylmethyl benzoate (4b-1).
- the third step 4-(((2S,4S)-4-(cyclopropylmethoxy)-2-(4-((cyclopropylmethoxy)carbonyl)phenyl)piperidin-1-yl )methyl)-5-methoxy-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester (4c-1)
- the fourth step 4-((2S,4S)-4-(cyclopropylmethoxy)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl )piperidin-2-yl)benzoic acid (compound 4)
- Preparation method Dissolve the crude product in methanol and dimethyl sulfoxide, and filter it with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/ammonium acetate aqueous solution containing 5mmol/L.
- Gradient elution method acetonitrile was eluted 60% by 5% gradient (elution time 15min), and lyophilized to obtain 4-((2S,4S)-4-(cyclopropylmethoxy)-1-((5- Methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (compound 4) (5 mg).
- the compound 5b is the structure 5b-B.
- the third step the maleate salt of methyl 4-((2S)-4-cyclopropylpiperidin-2-yl)benzoate [5c (diastereomer 1)]
- (2S)-4-cyclopropyl-2-(4-(methoxycarbonyl)phenyl)piperidine-1-carboxylic acid benzyl ester (2.0g, 5.08mmol) was dissolved in 50mL acetonitrile, slowly Add iodotrimethylsilane (5.1 g, 25.5 mmol) dropwise, and stir at room temperature for 30 min.
- compound 5c (diastereomer 1) is structure 5c-B.
- the fourth step 4-(((2S)-4-cyclopropyl-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7 -Methyl-1H-indole-1-carboxylic acid tert-butyl ester [5d (diastereomer 1)]
- the maleate salt (1.2 g) of the above crude methyl 4-((2S)-4-cyclopropylpiperidin-2-yl)benzoate [5c (diastereomer 1)] was dissolved in 50 mL of ethanol , add tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate (1.23g, 4.25mmol) (see WO2015009616 for the synthesis method), add 135mg Ir(CO) 2 acac, heated to 75°C, and reacted for 16h under a hydrogen balloon atmosphere.
- compound 5d (diastereomer 1) is structure 5d-B.
- compound 5 (diastereomer 1) is structure 5-B.
- the compound 5b-1 is structure 5b-A.
- the compound 5c-1 (diastereomer 2) is structure 5c-A.
- the third step 4-(((2S)-4-cyclopropyl-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7 -Methyl-1H-indole-1-carboxylic acid tert-butyl ester [5d-1 (diastereomer 2)]
- the compound 5d-1 (diastereomer 2) is structure 5d-A.
- compound 5-1 (diastereomer 2) is structure 5-A.
- Embodiment 6 is a diagrammatic representation of Embodiment 6
- tert-butyl 4-formyl-5-hydroxy-7-methyl-1H-indole-1-carboxylate (6a) (see WO2020016749 for the synthesis method) (0.3 g, 1.09 mmol) in 5 mL of DMF and add solid Potassium carbonate (0.2g, 1.45mmol) was added, and deuterated methyl iodide (0.32g, 2.21mmol) was added, and reacted at room temperature for 3h after the addition was completed.
- the third step 4-((7S)-8-((5-(methoxy-d3)-7-methyl-1H-indol-4-yl)methyl)-1-oxa-8- Trifluoroacetate salt of azaspiro[4.5]dec-7-yl)benzoic acid (compound 6)
- reaction solution was cooled to room temperature, concentrated under reduced pressure, 10 mL of tetrahydrofuran, 2 mL of water and 2 mL of methanol were added to the residue in sequence, and lithium hydroxide monohydrate (0.1 g, 2.38 mmol) was added, and reacted at room temperature for 16 h.
- Preparation method Dissolve the crude product in methanol and dimethyl sulfoxide, and filter it with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/water (containing 0.1% TFA).
- Gradient elution method acetonitrile was eluted 60% by 5% gradient (elution time 15min), and lyophilized to obtain 4-((7S)-8-((5-(methoxyl-d3)-7-methyl- 1H-indol-4-yl)methyl)-1-oxa-8-azaspiro[4.5]dec-7-yl)benzoic acid (compound 6) trifluoroacetate salt (0.085 g).
- Compound 6 is one of the isomers of structure 6-A or 6-B.
- Embodiment 7 is a diagrammatic representation of Embodiment 7:
- the first step 4-(((2S)-4-cyclopropyl-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-(methoxyl- d3)-tert-butyl 7-methyl-1H-indole-1-carboxylate [7a (diastereomer 1)]
- the maleate salt (235 mg) of the above crude methyl 4-((2S)-4-cyclopropylpiperidin-2-yl)benzoate [5c (diastereomer 1)] was dissolved in 10 mL of ethanol, Add tert-butyl 4-formyl-5-trideuteromethoxy-7-methyl-1H-indole-1-carboxylate (6b) (165 mg, 0.564 mmol), add 20 mg Ir(CO) 2 acac, The hydrogen was replaced three times, the temperature was raised to 80°C, and the reaction was carried out under a hydrogen balloon atmosphere for 16 hours.
- compound 7a (diastereomer 1) is structure 7a-B.
- compound 7 (diastereomer 1) is structure 7-B.
- Embodiment 8 is a diagrammatic representation of Embodiment 8
- Compound 8c (Diastereomer 1) is one of the isomers of structure 8c-A or 8c-B.
- the third step 4-(((2S)-4-cyclobutyl-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7 -Methyl-1H-indole-1-carboxylic acid tert-butyl ester [8d (diastereomer 1)]
- Compound 8d (Diastereomer 1) is one of the isomers of structure 8d-A or 8d-B.
- Compound 8 (Diastereomer 1) is one of the isomers of structure 8-A or 8-B.
- Embodiment 9 is a diagrammatic representation of Embodiment 9:
- the third step 4-((((2S)-4-(azetidin-1-yl)-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl) -5-methoxy-7-methyl-1H-indole-1-carboxylic acid tert-butyl ester (9c)
- the maleate salt (1.5 g) of the above crude product 4-((2S)-4-(azetidin-1-yl)piperidin-2-yl)benzoate (9b) was dissolved in 60 mL of ethanol , add tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate (see WO2015009616 for the synthesis method) (1.18g, 4.08mmol), add 46mg Ir(CO) 2 acac, heated to 75°C, and reacted for 48h under a hydrogen balloon atmosphere.
- reaction solution was cooled to room temperature, adjusted to pH 7 with 5mol/L hydrochloric acid aqueous solution, concentrated under reduced pressure, and the crude product was passed through Pre-HPLC (instrument and preparative column: adopt SHIMADZU LC -20AP preparation liquid phase, the preparation column model is Phenomenex C18).
- Preparation method the crude product is dissolved with methanol and dimethyl sulfoxide, and filtered with a 0.45 ⁇ m filter membrane to prepare a sample solution.
- Mobile phase system acetonitrile/water.
- Compound 9 (Diastereomer 1) is one of the isomers of structure 9-A or 9-B.
- reaction solution was cooled to room temperature, concentrated under reduced pressure, adjusted to pH 12 with 5 mol/L sodium hydroxide solution, extracted with 200 mL of dichloromethane, separated the organic phase, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product (2S )-benzyl 4-formyl-2-(4-(methoxycarbonyl)phenyl)piperidine-1-carboxylate (10a) (3.5 g).
- Compound 10b (diastereomer 1) is one of the isomers of structure 10b-A or 10b-B, and it was confirmed by NMR 1 H- 1 H NOESY analysis that compound 10b (diastereomer 1) is structure 10b-A . .
- Compound 10c (diastereomer 1) is one of the isomers of structure 10c-A or 10c-B. According to the NMR analysis of compound 10b (diastereomer 1), it is confirmed that compound 10c (diastereomer 1) is Structure 10c-A.
Abstract
Description
序号 | 化合物编号 | IC 50(nM) |
1 | 化合物1-a的三氟乙酸盐 | A |
2 | 化合物2-a(非对映体1)的三氟乙酸盐 | A |
3 | 化合物2-b(非对映体2)的三氟乙酸盐 | A |
4 | 化合物3的三氟乙酸盐 | A |
5 | 化合物4 | A |
6 | 化合物5(非对映体1)的三氟乙酸盐 | A |
7 | 化合物5-1(非对映体2)的三氟乙酸盐 | A |
8 | 化合物6的三氟乙酸盐 | A |
9 | [化合物7(非对映体1)]的三氟乙酸盐 | A |
10 | [化合物8(非对映体1)]的甲酸盐 | A |
11 | 化合物10(非对映体1) | A |
12 | 化合物11(非对映体1)的铵盐 | A |
13 | 化合物12的铵盐 | A |
14 | 化合物13 | A |
15 | 化合物27-1 | A |
序号 | 化合物编号 | IC 50(nM) |
1 | 化合物1-a的三氟乙酸盐 | A |
2 | 化合物2-b(非对映体2)的三氟乙酸盐 | A |
3 | 化合物4 | A |
4 | 化合物5(非对映体1)的三氟乙酸盐 | A |
5 | 化合物6的三氟乙酸盐 | A |
序号 | 化合物编号 | 剂量 | 抑制率 |
1 | 对照化合物(LNP023)的三氟乙酸盐 | 60mg/kg | 37.36% |
2 | 化合物2-b(非对映体2)的三氟乙酸盐 | 60mg/kg | 73.12% |
3 | 化合物2-b(非对映体2)的三氟乙酸盐 | 30mg/kg | 35.04% |
受试化合物 | 给药方式* | AUC 0-t(ng/mL·h) | F% |
化合物5(非对映体1)的三氟乙酸盐 | i.g.(10mg/kg) | 15884 | 81.5 |
Claims (20)
- 一种化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,其中化合物选自通式(I)所述的化合物,R 1选自H、卤素、OH、氰基、NH 2、C 1-6烷基、C 2-6烯基、C 2-6炔基、C 1-6烷氧基、-C(=O)C 1-6烷基、-S(=O) pC 1-6烷基、-W-R 1d、-CH 2NHC(O)C 1-4烷基、-CH 2C(=O)R 1c、-OCH 2C(=O)R 1c、C 3-8碳环基或3至10元杂环基,其中所述烷基、烯基、炔基、烷氧基、碳环基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 2-6炔基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;p选自0、1或2;n选自0、1或2;W选自O或S;R 2选自卤素、C 1-6烷基或C 1-6烷氧基,其中所述烷基或烷氧基任选进一步被0至4个选自H、D、卤素、OH、氰基或NH 2的取代基所取代;X 1和X 2各自独立选自N或CR 3;Y选自NR 7或C(R 7) 2;R 6各自独立选自H、卤素、OH、-NR 1aR 1b、C 1-6烷基或C 1-6烷氧基,其中所述烷基、烷氧基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 7各自独立选自H、卤素、OH、-NR 1aR 1b、C 1-6烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、-C(=O)R 1d、-S(=O) 2R 1d、C 3-8碳环基或3至10元杂环基,其中所述烷基、烯基、炔基、烷氧基、碳环基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;作为选择,两个R 7和与其相连的碳原子一起形成3-6元杂环基,其中所述杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、-C(=O)R 1d、-S(=O) 2R 1d、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3-6元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;作为选择,相邻位置的R 6与R 7可以形成双键;作为选择,两个R 6和与其相连的原子一起形成C 3-6环烷基或3-6元杂环基,其中所述环烷基或杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、或者氰基取代的C 1-6烷基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 3各自独立选自H、卤素、氰基、C 1-6烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、-CH 2C(=O)R 1c、-S(=O) pC 1-6烷基、-CH 2NHC(O)C 1-4烷基、-OCH 2C(=O)R 1c、C 3-6碳环基或5至6元杂芳基,其中所述烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、碳环基或杂芳基任选进一步被0至4个H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基或杂芳基含有1至4个选自O、S或N的杂原子;R 1c选自OH、NH 2、C 1-6烷氧基、NHC 1-4烷基或N(C 1-4烷基) 2;R选自H、C 1-6烷基,其中所述烷基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、或者氰基取代的C 1-6烷基的取代基所取代;R 4选自C 5-12碳环基、5至12元杂环基、C 6-12芳基或5至12元杂芳基,其中所述碳环基、杂环基、芳基或杂芳基任选进一步被0至4个R 5取代,其中所述杂环基或杂芳基含有1至4个选自O、S或N的杂原子;R 5各自独立选自H、卤素、OH、氰基、-C(=O)R 4e、-S(=O) 2R 4e、-CH 2C(=O)R 4e、-C(=O)NHS(=O) 2R 4e、-C(=O)NR 4eR 4f、-S(=O) 2NHC(=O)R 4e、-S(=O) 2NR 4eR 4f、-P(O)R 4cR 4d、 C 1-6烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、C 3-10环烷基或4至12元杂环基,其中所述烷基、烷氧基、烯基、炔基、环烷基或杂环基任选进一步被0至4个H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基或C 3-6环烷基的取代基所取代,其中所述杂环基含有1至5个选自O、S或N的杂原子;R 4a、R 4b各自独立选自H、OH、氰基、-NR 1aR 1b、C 1-6烷基、C 1-6烷氧基、C 3-8碳环基、4至10元杂环基、C 6-10芳基或5至10元杂芳基,其中所述烷基、碳环基、杂环基、芳基或杂芳基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至10元杂环基或3至8元杂环基、杂芳基含有1至4个选自O、S或N的杂原子;R 4c、R 4d各自独立选自H、OH、C 1-6烷基、C 1-6烷氧基、-NR 1aR 1b、-OR 1d、-C 3-8碳环基、4至10元杂环基、C 6-10芳基或5至10元杂芳基,其中所述烷基、烷氧基、碳环基、杂环基、芳基或杂芳基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至10元杂环基或3至8元杂环基、杂芳基含有1至4个选自O、S或N的杂原子;R 4e、R 4f各自独立选自H、OH、-NR 1aR 1b、C 1-6烷基、C 1-6烷氧基、C 3-8环烷基、或5至12元杂环基,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 1a、R 1b各自独立选自H、C 1-6烷基,其中所述烷基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 1d各自独立选自H、C 1-6烷基、C 3-8碳环基或4至10元杂环基,其中所述烷基、碳环基或杂环基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;R 8选自H、卤素、OH、氰基、NH 2、C 1-6烷基、C 2-6烯基、C 2-6炔基、C 1-6烷氧基、-S(=O) pC 1-6烷基、-CH 2NHC(O)C 1-4烷基、-OCH 2C(=O)R 1c、C 3-8碳环基或3至10元杂环基,其中所述烷基、烯基、炔基、烷氧基、碳环基或杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;R 9或R 10各自独立选自H、卤素、OH、氰基、NH 2、C 1-6烷基、C 2-6烯基、C 2-6炔基、C 1-6烷氧基、C 1-6烷硫基、C 3-8碳环基或3至10元杂环基,其中所述烷基、烯基、炔基、烷氧基、烷硫基、碳环基或杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;当Y选自C(R 7) 2,R 7选自H、OH、-NR 1aR 1b、未取代的C 1-6烷基、羟基C 1-6烷基、氰基C 1-6烷基或未取代的C 1-6烷氧基,且两个R 7和与其相连的碳原子未一起形成3-6元杂环基时,需满足如下条件之一:1)R 1选自C 2-6炔基、C 3-6环烷基取代的C 1-6烷基、3至8元杂环基取代的C 1-6烷基、-W-C 3-8碳环基或-W-4至10元杂环基,其中所述炔基、烷基、碳环基、杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 2-6炔基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、氰基取代的C 1-6烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至10元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;2)相邻位置的R 6与R 7形成双键;3)两个R 6和与其相连的原子一起形成C 3-6环烷基或3-6元杂环基,其中所述环烷基或杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-6烷基、C 1-6烷氧基、卤素取代的C 1-6烷基、羟基取代的C 1-6烷基、或者氰基取代的C 1-6烷基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;4)X 2选自N。
- 根据权利要求1所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,R 1选自H、卤素、OH、氰基、NH 2、C 1-4烷基、C 2-4烯基、C 2-4炔基、C 1-4烷氧基、-C(=O)C 1-4烷基、-S(=O) pC 1-4烷基、-W-R 1d、-CH 2NHC(O)C 1-4烷基、-CH 2C(=O)R 1c、-OCH 2C(=O)R 1c、C 3-6碳环基或4至8元杂环基,其中所述烷基、烯基、炔基、烷氧基、碳环 基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2- 4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至8元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;R 2选自卤素、C 1-4烷基或C 1-4烷氧基,其中所述烷基、烷氧基任选进一步被0至4个选自H、D、卤素、OH、氰基或NH 2的取代基所取代;X 1和X 2各自独立选自N或CR 3;R 6各自独立选自H、卤素、OH、-NR 1aR 1b、C 1-4烷基或C 1-4烷氧基,其中所述烷基、烷氧基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 7各自独立选自H、卤素、OH、-NR 1aR 1b、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、-C(=O)R 1d、-S(=O) 2R 1d、C 3-6碳环基或3至8元杂环基,其中所述烷基、烯基、炔基、烷氧基、碳环基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至8元杂环基各自含有1至4个选自O、S或N的杂原子;作为选择,两个R 7和与其相连的碳原子一起形成3-6元杂环基,其中所述杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、-C(=O)R 1d、-S(=O) 2R 1d、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3-6元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;作为选择,相邻位置的R 6与R 7可以形成双键;作为选择,两个R 6和与其相连的原子一起形成C 3-6环烷基或3-6元杂环基,其中所述环烷基、杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 3各自独立选自H、卤素、氰基、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、-CH 2C(=O)R 1c、-S(=O) pC 1-4烷基、-CH 2NHC(O)C 1-4烷基、-OCH 2C(=O)R 1c、C 3-6碳环基或5至6元杂芳基,其中所述烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、碳环基或杂芳基任选进一步被0至4个H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代,其中所述杂芳基含有1至4个选自O、S或N的杂原子;R 1c选自OH、NH 2、C 1-4烷氧基、NHC 1-4烷基或N(C 1-4烷基) 2;R选自H、C 1-4烷基,其中所述烷基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 4选自C 5-7单环碳环基、C 5-12并环碳环基、C 5-12螺环碳环基、C 5-12元桥环碳环基、5至7元单环杂环基、5至12元并环杂环基、5至12元螺环杂环基或5至12元的桥环杂环基、 C 6-10芳基或5至10元杂芳基,其中所述碳环基、杂环基、芳基或杂芳基任选进一步被0至4个R 5所取代,其中所述杂环基或杂芳基含有1至4个选自O、S或N的杂原子;R 5各自独立选自H、卤素、OH、氰基、-C(=O)R 4e、-S(=O) 2R 4e、-CH 2C(=O)R 4e、-C(=O)NHS(=O) 2R 4e、-C(=O)NR 4eR 4f、-S(=O) 2NHC(=O)R 4e、-S(=O) 2NR 4eR 4f、-P(O)R 4cR 4d、 C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 3-8环烷基或4至10元杂环基,其中所述烷基、烷氧基、烯基、炔基、环烷基或杂环基任选进一步被0至4个H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基或C 3-6环烷基的取代基所取代,其中所述杂环基含有1至5个选自O、S或N的杂原子;R 4a、R 4b各自独立选自H、OH、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 3-6碳环基、4至8元杂环基、C 6-10芳基或5至6元杂芳基,其中所述烷基、碳环基、杂环基、芳基或杂芳基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至8元杂环基或3至8元杂环基、杂芳基含有1至4个选自O、S或N的杂原子;R 4c、R 4d各自独立选自H、OH、C 1-4烷基、C 1-4烷氧基、-NR 1aR 1b、-OR 1d、C 3-6碳环基、4至8元杂环基、C 6-10芳基或5至10元杂芳基,其中所述烷基、烷氧基、碳环基、杂环基、芳基或杂芳基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至8元杂环基或3至8元杂环基、杂芳基含有1至4个选自O、S或N的杂原子;R 4e、R 4f各自独立选自H、OH、-NR 1aR 1b、C 1-4烷基、C 1-4烷氧基或C 3-6环烷基、5至10元杂环基,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 1a、R 1b各自独立选自H、C 1-4烷基,其中所述烷基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 1d各自独立选自H、C 1-4烷基、C 3-6碳环基或4至8元杂环基,其中所述烷基、碳环基或杂环基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至8元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;R 8、R 9或R 10各自独立选自H、卤素、OH、氰基、NH 2、C 1-4烷基、C 2-4烯基、C 2-4炔基、C 1-4烷氧基、C 1-4烷硫基,其中所述烷基、烯基、炔基、烷氧基、烷硫基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;当Y选自C(R 7) 2,R 7选自H、OH、-NR 1aR 1b、未取代的C 1-4烷基、羟基C 1-4烷基、氰基C 1-4烷基或未取代的C 1-4烷氧基,且两个R 7和与其相连的碳原子未一起形成3-6元杂环基时,需满足如下条件之一:1)R 1选自C 2-4炔基、C 3-6环烷基取代的C 1-4烷基、3至8元杂环基取代的C 1-4烷基、-W-C 3-6碳环基或-W-4至8元杂环基,其中所述炔基、烷基、碳环基、杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至8元杂环基或4至8元杂环基含有1至4个选自O、S或N的杂原子;2)相邻位置的R 6与R 7形成双键;3)两个R 6和与其相连的原子一起形成C 3-6环烷基或3-6元杂环基,其中所述环烷基或杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1- 4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;4)X 2选自N。
- 根据权利要求2所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,R 1选自H、卤素、OH、氰基、NH 2、C 1-4烷基、C 2-4烯基、C 2-4炔基、C 1-4烷氧基、C 1-4烷硫基、-W-R 1d、C 3-6碳环基或4至8元杂环基,其中所述烷基、烯基、炔基、烷氧基、烷硫基、碳环基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述4至8元杂环基或3至8元杂环基含有1至4个选自O、S或N的杂原子;R 2选自F、Cl、Br、I、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基任选进一步被0至4个选自H、D、F、Cl、Br、I、OH、氰基或NH 2的取代基所取代;R 3各自独立选自H、F、Cl、Br、I、氰基、甲基、乙基、丙基、异丙基、-CH 2C(=O)OH、-CH 2C(=O)NH 2,其中所述甲基、乙基、丙基或异丙基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 6各自独立选自H、F、Cl、Br、I、OH、NH 2、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R选自H、甲基、乙基、丙基或异丙基,其中所述甲基、乙基、丙基或异丙基任选进一步被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基或CF 3的取代基所取代;R 4选自C 5-6单环碳环基、C 5-10并环碳环基、C 5-11螺环碳环基、C 5-12元桥环碳环基、5至6元单环杂环基、5至10元并环杂环基、5至11元螺环杂环基、5至12元的桥环杂环基、C 6-10芳基或5至10元杂芳基,其中所述碳环基、杂环基、芳基或杂芳基任选进一步被0至4个R 5所取代,其中所述杂环基或杂芳基含有1至4个选自O、S或N的杂原子;R 5各自独立选自H、卤素、OH、氰基、-C(=O)R 4e、-S(=O) 2R 4e、-CH 2C(=O)R 4e、-C(=O)NHS(=O) 2R 4e、-C(=O)NR 4eR 4f、-S(=O) 2NHC(=O)R 4e、-S(=O) 2NR 4eR 4f、-P(O)R 4cR 4d、 C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 3-6环烷基或4至6元杂环基,其中所述烷基、烷氧基、烯基、炔基、环烷基或杂环基任选进一步被0至4个H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基或C 3-6环烷基的取代基所取代,其中所述杂环基含有1至5个选自O、S或N的杂原子;R 4a、R 4b、R 4c、R 4d各自独立选自H、OH、NH 2、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、环丙基或环丁基,其中所述甲基、乙基、丙基、异丙基、甲氧基、乙氧基、环丙基或环丁基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 1a、R 1b各自独立选自H、甲基、乙基、丙基或异丙基,其中所述甲基、乙基、丙基或异丙基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 4e、R 4f各自独立选自H、OH、NH 2、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、环丙基或环丁基;R 1d各自独立选自H、甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基、氧杂环丁基、氮杂环丁基、吡咯烷基或苯基,其中所述甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基、氧杂环丁基、氮杂环丁基、吡咯烷基或苯基任选被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 8、R 9或R 10各自独立选自H、F、Cl、Br、I、OH、氰基、CF 3、NH 2、甲基、乙基。
- 根据权利要求3所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,化合物选自通式(Ia)、(Ib)、(Ic)、(Id)、(Ie)或(If)所述的化合物,n各自独立选自0、1或2;R 3各自独立选自H、F、Cl、Br、I、氰基、甲基、乙基、丙基、异丙基、-CH 2C(=O)OH、-CH 2C(=O)NH 2,其中所述甲基、乙基、丙基或异丙基任选进一步被0至4个选自H、F、Cl、Br、I、OH、氰基的取代基所取代;R 6各自独立选自H、F、Cl、Br、I、OH、NH 2、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基或异丙氧基任选进一步被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基、甲氧基、乙氧基、CF 3、-CH 2F或-CH 2OH的取代基所取代;R 7各自独立选自H、F、Cl、Br、I、OH、NH 2、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基、炔丙基、-C(=O)R 1d、-S(=O) 2R 1d、环丙基、环丁基、环戊基、环己基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基、炔丙基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 7A选自H、F、Cl、Br、I、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、-C(=O)R 1d、-S(=O) 2R 1d、环丙基、环丁基、环戊基、环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、环丙基、环丁基、环戊基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 7a各自独立选自R d、F、Cl、Br、I、乙烯基、乙炔基、丙炔基、炔丙基、-C(=O)R 1d、-S(=O) 2R 1d、环丙基、环丁基、环戊基、环己基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基,其中所述乙烯基、乙炔基、丙炔基、炔丙基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R d各自独立选自甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基,所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基进一步被1至3个选自卤素、乙炔基、C 2-4炔基、C 1-4烷氧基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代;(Id)中,作为选择,两个R 7和与其相连的碳原子一起形成氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基,其中所述氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基任选进一步被0至4个选自H、卤素、OH、=O、氰基、-C(=O)R 1d、-S(=O) 2R 1d、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;或者(Id)中,两个R 6和与其相连的原子一起形成环丁基、环戊基、环己基、氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基;R 1A选自乙炔基、丙炔基、炔丙基、-CH 2-环丙基、-CH 2-环丁基、-CH 2-环戊基、-CH 2-氧杂环丁基、-CH 2-氮杂环丁基、-CH 2-吡咯烷基、-O-环丙基、-O-环丁基、-O-环戊基,所述乙炔基、丙炔基、炔丙基、-O-环丙基、-O-环丁基、-O-环戊基或-CH 2-任选进一步被0至2个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1- 4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 1各自独立选自H、F、Cl、Br、I、OH、氰基、NH 2、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基、炔丙基、甲硫基、乙硫基、环丙基、环丁基或-W-R 1d,其中所述甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基、炔丙基、甲硫基、乙硫基、环丙基、环丁基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 2-4炔基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 4各自独立选自环戊基、环己基、苯并环己基、苯并环戊基、苯基、萘基、吡啶基、吡唑基、嘧啶基或萘啶基,所述环戊基、环己基、苯并环己基、苯并环戊基、苯基、萘基、吡啶基、吡唑基、嘧啶基或萘啶基任选进一步被0至4个R 5取代;R 4a、R 4b、R 4c、R 4d各自独立选自H、OH、NH 2、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、环丙基或环丁基,其中所述甲基、乙基、丙基、异丙基、甲氧基、乙氧基、环丙基或环丁基任选进一步被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基或CF 3的取代基所取代;R 1d各自独立选自H、甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基、氧杂环丁基、氮杂环丁基、吡咯烷基或苯基,其中所述甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基、氧杂环丁基、氮杂环丁基、吡咯烷基或苯基任选被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基、甲氧基、乙氧基、CF 3、-CH 2F、-CH 2OH、环丙基、环丁基、氮杂环丁基或吡咯烷基的取代基所取代。
- 根据权利要求4所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,化合物选自通式(Id)所述的化合物,R 5各自独立选自H、F、Cl、Br、I、OH、氰基、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、异丙氧基、-COOH、-CH 2OH、-S(=O) 2NH 2、-S(=O) 2NHCH 3、-S(=O) 2OH、 -C(=O)NH 2、-C(=O)NHOH、-S(=O) 2NHC(=O)CH 3、-C(=O)NHS(=O) 2CH 3、吡唑基、四唑基,其中所述甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、异丙氧基、吡唑基、四唑基任选进一步被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基、甲氧基、乙氧基、CF 3、-CH 2F、-CH 2OH、环丙基或环丁基的取代基所取代;R 1各自独立选自H、F、Cl、Br、I、OH、氰基、NH 2、-OCD 3、CD 3、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、环丙基、乙炔基、-CH 2-环丙基或-O-环丙基;R 2各自独立选自F、Cl、Br、I、甲基、乙基、丙基、异丙基;或者R 2各自独立选自CD 3、CHD 2、CH 2D;R 3各自独立选自H、甲基或乙基;
- 根据权利要求4所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,化合物选自通式(Ia)、(Ib)、(Ic)、(Ie)或(If)所述的化合物,R 1A选自乙炔基、丙炔基、炔丙基、-CH 2-环丙基、-CH 2-环丁基、-CH 2-环戊基、-CH 2-氧杂环丁基、-CH 2-氮杂环丁基、-CH 2-吡咯烷基、-O-环丙基、-O-环丁基、-O-环戊基,所述乙炔基、丙炔基、炔丙基、-O-环丙基、-O-环丁基、-O-环戊基或-CH 2-任选进一步被0至2个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基、乙炔基、甲氧基、乙氧基、CF 3、-CH 2F、-CH 2OH、环丙基、环丁基、氮杂环丁基或吡咯烷基的取代基所取代;R 1各自独立选自H、F、Cl、Br、I、OH、氰基、NH 2、-OCD 3、CD 3、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、环丙基、乙炔基、-CH 2-环丙基或-O-环丙基;R 2各自独立选自F、Cl、Br、I、甲基、乙基、丙基、异丙基;或者R 2各自独立选自CD 3、CHD 2、CH 2D;R 3各自独立选自H、甲基或乙基;R 5各自独立选自H、F、Cl、Br、I、OH、氰基、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、异丙氧基、-COOH、-CH 2OH、-S(=O) 2NH 2、-S(=O) 2NHCH 3、-S(=O) 2OH、 -C(=O)NH 2、-C(=O)NHOH、-S(=O) 2NHC(=O)CH 3、-C(=O)NHS(=O) 2CH 3、吡唑基、四唑基,其中所述甲基、乙基、丙基、异丙基、甲氧基、乙 氧基、丙氧基、异丙氧基、吡唑基、四唑基任选进一步被0至4个选自H、F、Cl、Br、I、OH、=O、氰基、NH 2、甲基、乙基、甲氧基、乙氧基、CF 3、-CH 2F、-CH 2OH、环丙基或环丁基的取代基所取代;R 6各自独立选自H、F、Cl、Br、I、OH、NH 2、甲基、乙基、丙基、异丙基;R 7各自独立选自H、F、Cl、Br、I、OH、NH 2、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基、炔丙基、-CH 2-丙炔基、-CH 2-环丙基、-CH 2-环丁基、-CH 2-氮杂环丁基、-CH 2OCH 3、-OCH 2CH 2OCH 3、-CH 2CH 2OCH 3、-CH 2CF 3、-OCH 2-环丙基、-C(=O)CH 3、-C(=O)-环丙基、-C(=O)-苯基、-S(=O) 2CH 3、-S(=O) 2CH 2CH 3、-S(=O) 2-环丙基、-S(=O) 2-CH 2-环丙基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基;R 7A选自F、Cl、Br、I、甲基、乙基、丙基、异丙基、叔丁基、-CH 2-环丙基、-CH 2-环丁基、-CH 2-氮杂环丁基、-CH 2OCH 3、-CH 2CH 2OCH 3、-CH 2CF 3、-C(=O)CH 3、-C(=O)-环丙基、-C(=O)-苯基、-S(=O) 2CH 3、-S(=O) 2-环丙基、-S(=O) 2-CH 2-环丙基、环丙基、环丁基、环戊基或咪唑基;R 7a选自F、Cl、Br、I、CF 3、-CH 2F、乙烯基、乙炔基、丙炔基、炔丙基、-CH 2-丙炔基、-CH 2-环丙基、-CH 2-环丁基、-CH 2-氮杂环丁基、-CH 2OCH 3、-OCH 2CH 2OCH 3、-CH 2CH 2OCH 3、-CH 2CF 3、-OCH 2-环丙基、-C(=O)CH 3、-C(=O)-环丙基、-C(=O)-苯基、-S(=O) 2CH 3、-S(=O) 2CH 2CH 3、-S(=O) 2-环丙基、-S(=O) 2-CH 2-环丙基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基。
- 根据权利要求4所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,通式(Id)化合物选自通式(Id-1)或通式(Id-2)所示的化合物,R 1选自H、F、Cl、Br、I、-OCD 3、CD 3、甲基、乙基、丙基、甲氧基、乙氧基、异丙氧基、环丙基、-CH 2-环丙基或-O-环丙基;或者R 2各自独立选自CD 3、CHD 2、CH 2D;R 7选自甲氧基甲基、甲氧基乙基、环丙基、环丁基、环戊基、环己基、氮杂环丁基、氮杂环戊基、氮杂环己基、氧杂环丁基、氧杂环戊基、氧杂环己基、乙炔基、丙炔基或炔丙基,其中所述环丙基、环丁基、环戊基、环己基、氮杂环丁基、氮杂环戊基、氮杂环己基、氧杂环丁基、氧杂环戊基、氧杂环己基、乙炔基、丙炔基或炔丙基任选进一步被0至4个选自H、D、F、Cl、Br、CF 3、OH、=O、氰基、NH 2、甲基、甲氧基的取代基所取代;
- 根据权利要求2所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,通式(I)化合物选自通式(Id-3)、通式(Id-4)所示的化合物,环B选自3-6元杂环基,其中所述杂环基任选进一步被0至4个选自H、卤素、OH、=O、氰基、-C(=O)R 1d、-S(=O) 2R 1d、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基3-6元杂环基或3至8元含有1至4个选自O、S或N的杂原子;R 6各自独立选自H、卤素、OH、NH 2、C 1-4烷基或C 1-4烷氧基,其中所述烷基或者烷氧基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 7选自C 2-4炔基、C 3-6碳环基、3至8元杂环基,R 7’选自H、卤素、OH、-NR 1aR 1b、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、-C(=O)R 1d、-S(=O) 2R 1d,其中所述烷基、烯基、炔基、烷氧基、碳环基或杂环基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述3至8元杂环基各自含有1至4个选自O、S或N的杂原子。
- 根据权利要求8所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,X 1选自N或者CH,X 2选自N或者CH,其中所述CH任选被1个甲基或乙基取代;环B选自3-6元杂环烷基,其中所述杂环烷基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、-C(=O)C 1-4烷基、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基、杂环烷基含有1至4个选自O、S或N的杂原子;R 7选自C 2-4炔基、苯基、C 3-6环烷基、3至8元杂环烷基或者5-6元杂芳基,R 7’选自H、卤素、OH、-NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、-C(=O)C 1-4烷基、-S(=O) 2C 1-4烷基,其中所述烷基、烯基、炔基、烷氧基、苯基、环烷基、杂芳基、杂环烷基任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环烷基、杂环基或杂芳基含有1至4个选自O、S或N的杂原子;优选地,环B选自氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基,其中所述氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基任选进一步被0至4个选自H、卤素、OH、=O、氰基、NH 2、-C(=O)C 1-4烷基、C 1-4烷基、C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基的取代基所取代;R 7选自取代的或者未取代的如下基团之一:乙炔基、丙炔基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基,R 7’选自H、F、OH、NH 2,或者取代的或者未取代的如下基团之一:甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基或炔丙基,当R 7、R 7’被取代时,任选进一步被0至4个选自H、D、卤素、OH、=O、氰基、NH 2、C 1-4烷基、C 1-4烷氧基、C 2-4烯基、C 2-4炔基、C 1-4烷基取代的C 2-4烯基、C 1-4烷基取代的C 2-4炔基、C 1-4烷基氧取代的C 1-4烷氧基、卤素取代的C 1-4烷基、羟基取代的C 1-4烷基、氰基取代的C 1-4烷基、C 3-6环烷基或3至8元杂环基的取代基所取代,其中所述杂环基含有1至4个选自O、S或N的杂原子;R 6各自独立选自H、F、Cl、Br、CF 3、甲基或乙基;R 1、R 2、R 4的定义与权利要求5相同。
- 根据权利要求9所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,环B选自氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基,其中所述氧杂环丁基、氧杂环戊基、氧杂环己基、硫杂环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基任选进一步被0至4个选自H、F、Cl、Br、CF 3、OH、=O、氰基、NH 2、-C(=O)CH 3、甲基、乙基、甲氧基或乙氧基的取代基所取代;R 7选自取代的或者未取代的如下基团之一:乙炔基、丙炔基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基、哌嗪基、氧杂环丁基、氧杂环戊基、氧杂环己基、吡唑基、吡咯基、咪唑基、呋喃基、噻吩基、噻唑基、噁唑基、异噁唑基、三唑基、1,2,4-噁二唑基、吡啶基、哒嗪基、吡嗪基或嘧啶基,R 7’选自H、F、OH、NH 2,或者取代的或者未取代的如下基团之一:甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、异丙氧基、乙烯基、乙炔基、丙炔基或炔丙基,当R 7、R 7’被取代时,任选进一步被0至4个选自H、D、F、Cl、Br、CF 3、OH、=O、氰基、NH 2、甲基、乙基、甲氧基、乙氧基、乙炔基、丙炔基、炔丙基、环丙基、环丁基、环戊基、氮杂环丁基、吡咯烷基、哌啶基、吗啉基或哌嗪基的取代基所取代;R 1、R 2、R 4的定义与权利要求6相同。
- 根据权利要求1所述化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,其中该化合物选自表E-1所示结构之一。
- 一种药物组合物,包括权利要求1-15任意一项所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,以及要学上可接受的载体。
- 一种药物组合物或药物制剂,其中所述药物组合物或药物制剂包含1-600mg的权利要求1-15任意一项所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶和药用赋型剂。
- 根据权利要求1-15任意一项所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶或者权利要求16-17任一项所述的药物组合物在用于制备治疗与补体因子B活性或表达量相关疾病的药物中的应用。
- 根据权利要求17所述的应用,其特征在于,其中所述疾病选自肾脏疾病。
- 一种用于治疗哺乳动物的疾病的方法,所述方法包括给予受试者治疗有效量的权利要求1-15任意一项所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,治疗有效量优选1-600mg,其中所述疾病优选肾脏疾病。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3229360A CA3229360A1 (en) | 2021-08-18 | 2022-08-18 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine |
AU2022329230A AU2022329230A1 (en) | 2021-08-18 | 2022-08-18 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine |
IL310682A IL310682A (en) | 2021-08-18 | 2022-08-18 | The history of benzo a heteroaromatic ring containing nitrogen and its use in medicine |
KR1020247006312A KR20240049561A (ko) | 2021-08-18 | 2022-08-18 | 벤즈아제핀 방향족 고리 유도체 및 이의 의약에서의 응용 |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110940107 | 2021-08-18 | ||
CN202110940107.4 | 2021-08-18 | ||
CN202111048416 | 2021-09-08 | ||
CN202111048416.7 | 2021-09-08 | ||
CN202111532328 | 2021-12-16 | ||
CN202111532328.4 | 2021-12-16 | ||
CN202210255370.4 | 2022-03-22 | ||
CN202210255370 | 2022-03-22 | ||
CN202210496109 | 2022-05-12 | ||
CN202210496109.3 | 2022-05-12 | ||
CN202210558720 | 2022-05-25 | ||
CN202210558720.4 | 2022-05-25 | ||
CN202210903696 | 2022-07-29 | ||
CN202210903696.3 | 2022-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023020566A1 true WO2023020566A1 (zh) | 2023-02-23 |
Family
ID=85240066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/113216 WO2023020566A1 (zh) | 2021-08-18 | 2022-08-18 | 一种苯并氮杂芳环衍生物及其在医药上的应用 |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20240049561A (zh) |
AU (1) | AU2022329230A1 (zh) |
CA (1) | CA3229360A1 (zh) |
IL (1) | IL310682A (zh) |
TW (1) | TW202321212A (zh) |
WO (1) | WO2023020566A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139534A1 (en) * | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
WO2023246870A1 (zh) * | 2022-06-23 | 2023-12-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
WO2024046277A1 (zh) * | 2022-08-29 | 2024-03-07 | 南京明德新药研发有限公司 | 一系列含氮桥杂环化合物及其制备方法 |
WO2024049977A1 (en) * | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024051849A1 (en) * | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015009616A1 (en) | 2013-07-15 | 2015-01-22 | Novartis Ag | Piperidinyl indole derivatives and their use as complement factor b inhibitors |
CN109414441A (zh) * | 2016-06-27 | 2019-03-01 | 艾其林医药公司 | 治疗医学障碍的喹唑啉和吲哚化合物 |
WO2020016749A2 (en) | 2018-07-16 | 2020-01-23 | Novartis Ag | Chemical process for preparing phenylpiperidinyl indole derivatives |
CN111032042A (zh) * | 2017-08-31 | 2020-04-17 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的新用途 |
WO2022028507A1 (zh) | 2020-08-07 | 2022-02-10 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
CN114057758A (zh) * | 2020-08-07 | 2022-02-18 | 上海美悦生物科技发展有限公司 | 补体因子b抑制剂及其药物组合物、制备方法和用途 |
WO2022143940A1 (zh) * | 2020-12-30 | 2022-07-07 | 南京明德新药研发有限公司 | 一系列哌啶取代的苯酸类化合物及其应用 |
-
2022
- 2022-08-18 KR KR1020247006312A patent/KR20240049561A/ko unknown
- 2022-08-18 IL IL310682A patent/IL310682A/en unknown
- 2022-08-18 TW TW111131199A patent/TW202321212A/zh unknown
- 2022-08-18 AU AU2022329230A patent/AU2022329230A1/en active Pending
- 2022-08-18 WO PCT/CN2022/113216 patent/WO2023020566A1/zh active Application Filing
- 2022-08-18 CA CA3229360A patent/CA3229360A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015009616A1 (en) | 2013-07-15 | 2015-01-22 | Novartis Ag | Piperidinyl indole derivatives and their use as complement factor b inhibitors |
CN105579444A (zh) * | 2013-07-15 | 2016-05-11 | 诺华股份有限公司 | 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途 |
CN109414441A (zh) * | 2016-06-27 | 2019-03-01 | 艾其林医药公司 | 治疗医学障碍的喹唑啉和吲哚化合物 |
CN111032042A (zh) * | 2017-08-31 | 2020-04-17 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的新用途 |
WO2020016749A2 (en) | 2018-07-16 | 2020-01-23 | Novartis Ag | Chemical process for preparing phenylpiperidinyl indole derivatives |
WO2022028507A1 (zh) | 2020-08-07 | 2022-02-10 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
CN114057692A (zh) | 2020-08-07 | 2022-02-18 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
CN114057758A (zh) * | 2020-08-07 | 2022-02-18 | 上海美悦生物科技发展有限公司 | 补体因子b抑制剂及其药物组合物、制备方法和用途 |
WO2022143940A1 (zh) * | 2020-12-30 | 2022-07-07 | 南京明德新药研发有限公司 | 一系列哌啶取代的苯酸类化合物及其应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139534A1 (en) * | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
WO2023246870A1 (zh) * | 2022-06-23 | 2023-12-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
WO2024046277A1 (zh) * | 2022-08-29 | 2024-03-07 | 南京明德新药研发有限公司 | 一系列含氮桥杂环化合物及其制备方法 |
WO2024049977A1 (en) * | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2022329230A1 (en) | 2024-03-21 |
KR20240049561A (ko) | 2024-04-16 |
TW202321212A (zh) | 2023-06-01 |
CA3229360A1 (en) | 2023-02-23 |
IL310682A (en) | 2024-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023020566A1 (zh) | 一种苯并氮杂芳环衍生物及其在医药上的应用 | |
CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
TWI718207B (zh) | 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用 | |
CN109843873B (zh) | 炔代杂环化合物、其制备方法及其在医药学上的应用 | |
KR20150130415A (ko) | 질환의 치료에 유용한 헤테로환식 화합물 | |
WO2020216190A1 (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
JP6553615B2 (ja) | 疼痛に対して多重モードの活性を有するピペラジン誘導体 | |
US20170253587A1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
CN110461838B (zh) | 噁二唑瞬时受体电位通道抑制剂 | |
WO2019174577A1 (zh) | 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途 | |
CN102224142A (zh) | 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物 | |
WO2023143424A1 (zh) | 一种氮杂并环衍生物及其在医药上的应用 | |
WO2020244613A1 (zh) | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 | |
CN108779115A (zh) | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 | |
WO2023030453A1 (zh) | 一种降解Bcl-2家族蛋白的化合物及其在医药上的应用 | |
WO2023125182A1 (zh) | 一种丙酸衍生物及其在医药上的应用 | |
WO2022223039A1 (zh) | Sos1降解剂及其制备方法和应用 | |
TW202202500A (zh) | Pb2抑制劑及其製備方法和用途 | |
TW202132288A (zh) | Trek(twik相關的k+通道)通道功能的調節劑 | |
WO2024061366A1 (zh) | 具有磷酰化芳基结构的小分子化合物及其应用 | |
WO2023246833A1 (zh) | 一种五并五元环衍生物的药物组合物及其在医药上的应用 | |
CN118043314A (zh) | 一种苯并氮杂芳环衍生物及其在医药上的应用 | |
TWI727152B (zh) | 炔代雜環化合物、其製備方法及其在醫藥學上的應用 | |
WO2024051741A1 (zh) | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 | |
WO2024012570A1 (zh) | 一种含氮杂环衍生物及其组合物和药学上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22857877 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 310682 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202490196 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 808176 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3229360 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024002722 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20247006312 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022329230 Country of ref document: AU Ref document number: AU2022329230 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022857877 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022329230 Country of ref document: AU Date of ref document: 20220818 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022857877 Country of ref document: EP Effective date: 20240318 |